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Escherichia coli and Klebsiella pneumoniae cause a wide range of infections. 
Multidrug-resistance strains carrying extended-spectrum β-lactamases (ESBLs) has 
become a growing problem worldwide. The CTX-M type ESBLs has emerged 
distinctly, especially in Escherichia coli and Klebsiella pneumoniae. CTX-M type 
has been associated with many outbreaks of infections both in the hospitals and 
community. CTX-M-15 is now identified as the most predominantly distributed 
CTX-M enzyme. Clonal outbreaks of CTX-M-15 producing Enterobacteriaceae have 
been described in many countries including the United Kingdom, and Escherichia 
coli is the most commonly involved species.  
A total of 100 isolates were received in 2010 from London St George’s hospital, 
England, 50 Escherichia coli, 17 Klebsiella spp, 9 Enterobacter spp, 13 Proteus spp, 
6 Lactose fermenting coliforms, 2 Pantoea spp, one Serratia marcescens, one 
Morganella morganii, and one Hafnia alvei. The antimicrobial susceptibility results 
showed that 5 Escherichia coli and one Klebsiella pneumoniae isolates were found to 
be resistance to cefotaxime, ceftazidime, ceftriaxone, cefotaxime, , ciprofloxacin, , 
and gentamicin, making them multi-drug resistant bacteria. None of the isolates 
showed resistance to imipenem, ertapenem, or morepenem, thus making 
carbapenems the drug of choice for the treatment of these infections due to multi-
resistant isolates. The overall frequency of CTX-M-15 type ESBL-producers 
detected in this study was 6 (6%) most of them 5/6 (83%) were from Escherichia coli 
and one was (17%) Klebsiella pneumoniae isolates. The 6 CTX-M-positive isolates 
were typed by PFGE, only two strains of Escherichia coli showed more than 85% 
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similarity, owing to clonal homology for both strains. The rest strains showed less 
than 85% similarity.  
S1 nuclease plasmid profiles were obtained for ESBL-producers isolates. A total of 
one to three plasmids per isolate, ranging from approximately 78.0 to 152.0 kb, were 
observed. The plasmids from most isolates were assigned to be IncFA and IncFB 
replicons. Analysis of phylogenetic groups showed group A and group B2. The 
method of phylogenetic classification of exteraintestinal pathogenic Escherichia coli 
depends on examine and combination of two preserved genes (chuaA and yjaA) and 
the DNA fragment TSP. 
Primer walking and PCR experiments were used for the genetic environment studies 
which showed 5 different genetic constructions for the described blaCTX-M-15 genes. 
Conjugation studies were used to detect the transferability of the plasmids harbouring 
the reported blaCTX-M-15 genes. Three isolates were found transferable by conjugation.  
In conclusion, this study reports the presence of hospital highly resistant blaCTX-M-15 
in St George’s hospital. The spread of blaCTX-M-15 is probably due to horizontal gene 
transfer harbouring ISEcp1 and the conjugative properties of plasmids carrying 
blaCTX-M-15.  
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Paper presented at the 22nd ECCMID, London 2012 
M.S. Alqurashi, J. Dave, M. Pond and S.G.B. Amyes 
The role of plasmids in the control of antibiotic resistance in 
Escherichia coli and Klebsiella pneumoniae isolated from St George’s 
Hospital London 
Objectives: The aim of this study was to investigate the infiltration of extended-spectrum β-
lactamases (ESBLs) and their association with individual clones of Enterobacteriaceae 
isolated from blood cultures within a London teaching hospital. 
Methods: One hundred Enterobacteriaceae, isolated sequentially in August - October 2009 
from blood culture specimens, were obtained from St George's Hospital London. 
Antimicrobial susceptibility testing was determined by disc diffusion and agar dilution was 
used to measure the MICs of Cefotaxime, Ceftazidime, and Ceftriaxone; all tests were 
interpreted according to the BSAC guidelines. Multiplex PCR was used to identify CTX-M 
and AmpC enzymes. Pulsed-field gel electrophoresis (PFGE) with Xba1 restriction was used 
to genotype the strains. Plasmid profiles were determined using S1 nuclease and alkaline 
lysis extraction and examined by PFGE. Furthermore, PCR based replicon typing was used 
to identify individual plasmid types. 
Results: Six isolates showed resistance to cefotaxime, ceftazidime and ceftriaxone, five were 
Escherichia coli and one was Klebsiella pneumoniae. All of them possessed the CTX-M-15 
β-lactamase gene but none of the strains harboured any of the known transferable AmpC β-
lactamases. Genotyping by PFGE revealed that two of the CTX-M-15 
β-lactamase-containing isolates of Escherichia coli were closely related but the remaining 
isolates were less than 80% identical. In the six isolates, the plasmid profiles were not 
identical, ranging from 97.0kb to 145.5kb though four isolates of Escherichia coli did have 
the same plasmid of 145.5kb. 
Conclusion: Our data indicate the presence of plasmids carrying the CTX-M-15 β-lactamase 
within this Enterobacteriaceae population and suggest that the dissemination of CTX-M-15 
β-lactamase gene is linked to both the transfer of these genes between plasmids and the 
transfer of those plasmids between the individual strains. 
 
Published in Clinical Microbiology and Infection (2012) 18: S333.   
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Abbreviations   
Å  Angstroms  
A. baumannii  Acinetobacteri baumannii  
Β  β  
bla  β-lactamase  
BLAST  Basic Local Alignment Search Tool  
BSAC  British Society of Antimicrobial Agents and Chemotherapy  
CLSI  Clinical Laboratory Standards Institute  
CTX-M  Cefotaxime  
DNA  Deoxyribonucleic acid  
E. aerogenes  Enterobacter aerogenes  
E. coli  Escherichia coli  
EDTA  Ethylenediaminetetraacetic Acid  
ESBL  Extended-spectrum-β-lactamase  
EUCAST  European Committee on antimicrobial susceptibility testing  
GW-PCR  Genome walking-polymerase chain reaction  
Inc  Incompatibility  
K.  Kluyvera  
Kb  Kilo-base pairs  
K. pneumoniae  Klebsiella pneumoniae  
L  Litre  
MBLs  Metallo-β-lactamases  
MDR  Multi-drug resistance/resistant  
Mg  Milligram  
MIC  Minimum inhibitory concentration  
mL  Milli-Litre  
mM  Milli-Molar  
M  Molar  
MGE  Mobile genetic elements  
μ  micro  
μg  microgram  
NCBI  National Centre of Biotechnology Information  
NCCLS  National Committee for Clinical Laboratory Standards  
P. aeruginosa  Pseudomonas aeruginosa  
PBP  Penicillin-binding protein  
PCR  Polymerase chain reaction  
PFGE  Pulsed-field gel electrophoresis  
pH  Measure of acidity or basicity of a solution  
PK  Proteinase K  
S. aureus  Staphylococcus aureus  
SDS  Sodium dodecyl sulphate  
Spp.  species  
TAE  Tris/acetic acid/ethylenediaminetetraacetic acid  
TBE  Tris/Borate/ethylenediaminetetraacetic acid  
TE  Tris/EDTA  
U  Units  
UTI  Urinary tract infection  
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1.1. Antimicrobial agents 
1.1.1 Definition 
The term antibiotic has traditionally indicated to natural metabolic products of fungi, 
actinomycetes, and bacteria that inhibit or kill the growth of microorganisms. 
Antibiotic production has been particularly linked with soil microorganisms and in 
the natural environment is believed to provide a selective advantage for organisms in 
their competition for nutrients and space. While the majority of antimicrobial agents 
in clinical use today are made from natural products of fermentation, most are then 
modified chemically (semi-synthetic) to improve their antibacterial or pharmacologic 
properties. Nonetheless, some agents are totally synthetic such as sulphonamides and 
quinolones. Therefore the name antibacterial or antimicrobial agent is often used in 





1.1.2. Historical prospective  
Antimicrobial agents have been used for the treatment of infectious diseases since 
the 17th century such as quinine for malaria (Hien & White, 1993) and emetine for 
amebiasis (Knight, 1980). during the first decade of 20th century, Paul Ehrlich was 
the first to propose the relation between microbial pathogens and drugs, as his 
experiments led to the arsphenamines for the treatment of syphilis (Montes & Cueva, 
1967). The present era of antimicrobial chemotherapy began in 1935, with the 
discovery of the sulphonamides by Gerhard Domagk (Otten, 1986). In 1929, 
penicillin was discovered by Alexander Fleming and he proposed that penicillin 
could be an effective chemotherapeutic agent (Fleming, 1929). However, Fleming 
was unable to exploit this clinically and it was left to Florey and Chain to purify 
penicillin and prepare it for clinical use in 1940 (Chain & Florey, 1940). Penicillin 
was only active against Gram-positive bacteria and it was not until Selman Waksman 
discovered streptomycin from soil bacterium Streptomyces griseus in the late 1940s, 
so Gram-negative bacteria became treatable with antibiotics (Schatz et al, 1944). 
From this discovery, many new classes of antibiotic had been described by the 1960s 
(Kingston, 2004). The semisynthetic penicillins introduced by Beecham in 1960s 
included methicillin, ampicillin and cloxacillin. Meanwhile, the cephalosporin C was 







1.1.3. Modes of action 
Antimicrobial drugs have several mechanisms (Brooks 2007; Amyes 2010) include: 
 
i) Interference with cell wall synthesis such as β-lactam antibiotics now 
include: penicillinase-resistant, amino-, carboxy-, indanyl-, and ureidopenicillins; 
first- to fifth-generation cephalosporins; monobactams; and 
carbapenems. 
ii) Interference of protein synthesis: Aminoglycosides, Macrolides, 
Tetracyclines, Lincomycins, Chloramphenicol, Linezolid, Streptogramins. 
iii) Interference with nucleic acid (DNA) synthesis by interfering with DNA 
gyrase and topoisomerase IV: Quinolones, Metronidazole. 
iv) Inhibition of Ribonucleic acid (RNA) synthesis by acting on DNAdirected 
RNA polymerase: Rifamycins. 
v) Inhibition of a metabolic pathway by acting on the synthesis of 
tetrahydropholic acid: Trimethoprim, Sulfamethoxazole. 
vi) Disruption of bacterial membrane structure: Polymyxins. 
1.1.4. Mechanisms of resistance to antimicrobials 
1.1.4.1. Intrinsic resistance 
The inherent resistance of bacteria to an antimicrobial may be expressed as a result 
of general adaptive processes that are not associated to a specific class of 
antimicrobials. For example, the natural low membrane permeability of 
Pseudomonas aeruginosais is most likely due to of its innate resistance to many 
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antimicrobials (Yoneyama & Katsumata, 2006). Other examples of intrinsic 
resistance are the outer membrane of Gram negative bacteria, the presence of genes 
giving resistance to self-produced antibiotics, general absence of the target hit by the 
antimicrobial or absence of bacterial uptake transport system for the antimicrobial ( 
(Normark and Normark, 2002)). 
 
1.1.4.2. Acquired resistance 
Acquired resistance causes most concern. Initially, a bacterial population may be 
susceptible to an agent then it acquires resistance under the selective pressure of that 
agent. Bacteria use several mechanisms to confer resistance, which then spread to a 
variety of bacterial species and genera (Wright, 2005). This active resistance includes 
three mechanisms: First, the bacteria may acquire genes encoding enzymes that 
destroy the antibacterial agent before it can act; an example of this is the 
β-lactamases (Abraham & Chain, 1940). Second, bacteria may possess efflux pumps 
that remove the antibiotic agent from the cell before it can bind to the target site 
(Levy & McMurray, 1974). The third, bacteria may possess genes for a metabolic 
by-pass pathway which creates na altered target; in the case of trimethoprim this 
would be an altered dihydrofolate reductase (Amyes & Smith, 1974) or, for the cell 
wall, an altered terminal residue on the peptidoglycan pentapeptide that is not 
capable of binding glycopeptides (Arthur & Courvalin, 1993). Finally bacteria may 
also limit the access of antibacterial agents by mutations in genes that regulate porins 




Bacteria may develop resistance by the acquisition of new genetic elements from 
other resistant bacteria; this termed horizontal evolution may take place between 
strain of the same species or different species and genera. Mechanisms of genetic 
exchange include conjugation, transduction and transformation (Thomas & Nielsen, 
2005). 
Mutations and selection, together with the genetic exchange mechanisms, may 
enable bacterial species to adapt rapidly to the introduction of antibacterial drugs into 
their environment. However, a single mutation may be sufficient for the bacteria to 
survive until they acquire additional mutations or additional genetic materials 
resulting in full resistance to the antimicrobial agent (Bushman, 2002; White et al, 
2005). 
 
1.1.5. β-lactam antibiotics 
1.1.5.1. Structure 
The β-lactam antibiotics include penicillins, cephalosporins, carbapenems, and 
monobactams. Their name comes from the presence of a β-lactam ring in their 
structure; this ring is vital for antimicrobial activity (Sherris, 2004) (Figure 1.1). In 
1940, Florey and Heatley travelled to the United States seeking help in mass 
production of penicillin by fermentation (Richards, 1943). They were able to isolate 
Penicillin from Penicillium chrysogenum. This work attracted pharmaceutical firms 
to invest in production of penicillin in enormous amount (Chain, 1979). Thereafter, 
different penicillin compounds were introduced by E.R. Squibb & Sons (Chain, 
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1979) and Florey’s group (Queener et al, 1986) producing benzyl-penicillin 
(Penicillin G) and 2-pentenylpenicillin respectively (Penicillin F) (Abraham et al, 
1949). It was later observed that both of penicillin forms contained β-lactam rings 





Figure 1.1: The structure of Penicillin nucleus. β-lactam ring is the square at the 
centre 
 
Scientists realized that early work applying different fermentation conditions were 
not that successful (Behrens et al, 1948). The β-lactam nucleus, which is 6-
aminopenicillanic acid (6-APA), proved to be the essential part of penicillin 
synthesis and modification. Therefore, Shaheen & Henery (1959) used acylation of 
chemically synthesized 6-APA to produce Penicillin V. This work the opportunity 
for new β-lactam agents to be produced by adding side chains to 6-APA. 
Subsequently, semi-synthetic β-lactam agents have been progressed continuously and 
systemically; for example, methicillin was the first semi-synthetic penicillin released 
in 1960 to resist hydrolysis by penicillinases (Fairbrother & Taylor, 1960) (Figure 
1.2). The use of natural sources continued to be searched through the production of 
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semi-synthetic agents. Cephalosporin C was isolated from Cephalosporium 
acremonium by Abraham and Newton (Abraham & Newton, 1961). This agent 
produced a novel family of β-lactam antibiotic where it possesses a nucleus of 7- 
aminocephalosporinic acid instead of 6-APA (Figure 1.3). Cephalosporin generations 
with effective broad spectrum activity have been released using 7-ACA as the 
precursor and isolated from bacteria. These include monobactam from pseudomonas 
acidophia (Imada et al, 1981), Chromobacterium violaceum (Skyes et al, 1981), and 
Agrobacterium radiobacter (Well et al, 1982), and carbapenem from Streptomyces 
spp (Nagarajan et al, 1971).  Carbapenems, such as imipenem and meropenem have 
become the antibiotic of choice for treatment of most serious bacterial infections, 
owing of its broadest spectrum of aerobic and anaerobic activity (Livermore & 
Woodford, 2006). The structures of carbapenems and penicillins chemically are 
similar except the sulphur atom in position 1 of the penicillin structure has been 
substituted with a carbon atom (Figure 1.4) (Kumagai et al, 2002). 
 
Figure 1.2: Methicillin structure shows the side chain attached to the β-lactam ring 




Figure 1.3: Cephalosporin C antibiotic shows 7- aminocephalosporinic acid 
  
 
Figure 1.4: General structure of carbapenems  
 
 
1.1.5.2. Mechanism of action of β-lactam antibiotics 
Bacteria depend on a heavily cross-linked peptidoglycan layer in the cell wall for the 
protection of cell shape and rigidity. Bacterial cell walls comprise a basic repeating 
unit of alternating disaccharides; N-acetyl glucosamine and N-acetyl muramic acid. 
The former sugar is modified by a unique pentapeptide. The composition of this 
pentapeptide varies between the Gram-positive and Gram-negative species, but 
always ends in two D-alanine residues. The individual peptidoglycan units are 
created inside the bacterial cell, but their final cross-linking is catalysed outside the 
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bacterial cytoplasmic membrane by a group of membrane anchored bacterial 
enzymes called the cell wall transpeptidase (Fisher et al, 2005; Wilk et al, 2005). In 
cross linking reaction, a peptide bond is built between the penultimate D-alanine on 
one chain and the free amino end of an L-lysine for Gram positive or a diamino 
pimelic acid for Gram negative residue on the other chain. The linkage is made with 
the penultimate D-alanine, resulting in the terminal D-alanine to be split in the 
process (Tipper & Strominger 1965; Ghuysen, 1988; Livermore & Williams, 1996; 
Wilk et al, 2005).  
 
β-lactam antibiotics inhibit the bacterial transpeptidase enzymes that use an active 
site serine and carry out their catalytic cycle. The later enzymes are referred as 
penicillin binding proteins (PBPs) (Spratt, 1994). The β-lactam drugs are able to do 
this, because they have stereochemical similarity with the D-alanine-D-alanine 
substrate. In the presence of penicillin, the transpeptidases create a lethal covalent 
penicilloyl-enzymes complex that aids to block the normal transpeptidation reaction. 
Consequently, weak cross linked peptidoglycan will occur, which induces the 
growing bacteria highly capable to cell lysis and death (Wilke et al, 2005).  
 
1.1.5.3. Mechanisms of resistance to β-lactam antibiotics 
β-lactam antibiotics perform their action by binding to the PBPs, thus inhibiting the 
synthesis of peptidoglycan. Inhibition of PBPs weakens the bacterial cell wall, 
resulting in cell growth inhibition and eventually leading to cell death. There are 
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three main mechanisms of β-lactam resistance; decreased access to the PBPs, 
decreased PBP binding affinity, and destruction of antibiotic by the expression of β-




1.1.5.3.1. Penicillin binding protein (PBP) modifications 
Because β-lactam antibiotics can inhibit peptidoglycan synthesis in all bacteria that 
possess a cell wall, a certain target must be present for these antibiotics. The 
existence of a specific PBP can be detected by mixing cell membranes with a 
radioactively labelled β-lactam compound, followed by electrophoretic separation to 
identify the protein species to which the β-lactam is covalently bound. All bacteria 
have several proteins that bind covalently with penicillin but have different affinities 
and specificities for various β-lactams. Three to seven PBPs may be present in any 
species having different enzymatic activities and may contain glycosyltransferases, 
peptidyltransferases, transpeptidases, endopeptidases and D-alanine 
carboxypeptidases (Frere et al, 1992).  
 
In Escherichia coli, there are seven major PBPs, each one of which can be 
inactivated by mutation or by treatment with a β-lactam having a high affinity for 
that PBP (Spratt, 1975; Spratt, 1977). PBP5 and PBP6 are present in the largest 
amounts and their carboxypeptidase activity hydrolyses the terminal D-alanine from 
the newly incorporated peptidoglycan pentapeptide; however neither enzyme is 
essential for cell growth (Spratt, 1980; Broome-Smith, 1985; Baquero et al, 1996). 
PBP3 is involved in septum formation and the β-lactams (ampicillin and cephalexin), 
with the highest affinity for PBP3, cause in the formation of long filaments or bulged 
cells that lack a division septum (Spratt, 1975; Botta et al, 1981). PBP2 appear to 
help determine cell shape because mutants lacking this activity or wild type cells 
inhibited by a β-lactam antibiotic specific for PBP2, form viable, ovoid shaped cells 
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(Spratt, 1975; Spratt & Pardee, 1975; Ogura et al, 1989). Treatment of Escherichia 
coli with a concentration of cephaloridine that will bind only PBP1B causes cell 
lysis, owing to the fact that this PBP is essential for synthesis of an integral cell wall 
and is the lethal target for this antibiotic. PBP1A and PBP1B also are blocked by 
cefsuloldin and are responsible for elongation or overall cell wall growth; these PBPs 
have both transpeptidase and transglycosylase activities. Therefore, various β-lactam 
antibiotics have the same mode of action by their covalent linkage to the enzymes 
responsible for modifying the newly incorporated peptidoglycan subunits. β-lactams 
can have different consequences for different bacteria owing of their preference for 
different PBPs, which carry out different enzymatic reactions or act at different sites 
in the growing cell wall (Suzuki et al, 1978; Yousif et al, 1985) . 
 
Overall, the PBPs from most bacteria have similar affinities for β-lactams. The 
variation in susceptibilities of different bacteria to β-lactams usually is not a 
consequence of the PBPs themselves, but of differences in the effective 
concentrations of the antibiotics at their site of action. Primary factors that determine 
the β-lactam level at the growing wall are the rate of diffusion of the antibiotic 
through the cell envelope and the susceptibility of the antibiotic to β-lactamases 
produced by the bacterium or its neighbours (Spratt, 1975; Spratt, 1977; Tomasz, 





1.1.5.3.2. Impermeability causing resistance 
The ability of the bacterial outer membrane to exclude hydrophobic molecules is an 
unusual feature among biologic membranes and serves to protect the bacterial cell (in 
case of enteric bacteria) from bile salts. Because of its lipid nature, the bacterial outer 
membrane is able to exclude hydrophilic molecules. However, the outer membrane 
has special channels, containing of protein molecules, called porins that allow the 
passive diffusion of low molecular weight hydrophilic compounds such as sugars, 
amino acids, and ions. Large antibiotic molecules penetrate the bacterial outer 
membrane relatively slowly, which accounts for the relatively high antibiotic 
resistance of Gram negative bacteria (Silver, 2003; Yoneyama & Katsumata, 2006). 
The permeability of the bacterial outer membrane varies widely from one Gram-
negative bacterium to another; for example, Pseudomonas aeruginosa is extremely 
resistant to antibiotics as the outer membrane is 100 times less permeable than that of 
Escherichia coli (Rachakonda & Cartee, 2004).  
 
Some Gram negative bacteria, such as Pseudomonas aeruginosa and Acinetobacter 
baumannii have an innate low susceptibility to β-lactam drugs, a feature that is 
linked to reduced outer membrane permeability (Nikaido, 2003). The reduced 
permeability in Pseudomonas aeruginosa is due to a low number of porins, which 
also tend to be small and have different chemical features when compared to the 
porins of the Enterobacteriaceae (Nestorovich et al, 2006). In other Gram negative 
bacteria like Citrobacter spp., Enterobacter spp., Escherichia coli and Klebsiella 
spp., β-lactam susceptibility is related to the existence of non-specific porins 
32 
 
belonging to the OmpC and OmpF groups (Davin-Régli & Pagès, 2006). Strains 
isolated from patients under antibiotic therapy, can express a characteristic reduction 
in cephalosporin and carbapenem susceptibility. A changed porin phenotype is also 
frequently associated with the exhibition of degradative enzymes such as 
β-lactamases, which provide a high level of β-lactam resistance (Nikaido, 1989; 
Pagès, 2004). 
 
1.1.5.3.3. Efflux pump 
Efflux pumps are transport proteins and have a role in the extrusion of toxic 
substrates such as antibiotics, from inside cells to the external environment. They can 
be recognised in both Gram-positive and Gram-negative bacteria and in eukaryotic as 
well (Bambeke et al, 2000). These pumps can be specific for one compound or can 
transport a range of structurally different compounds including antibiotics from a 
range of different classes. Such pumps may be associated with multiple drug 
resistance (MDR). Efflux pump as a mechanism of resistance was first described in 
the early 1980s for tetracycline (Ball et al, 1980). Thereafter, efflux pump-mediated 
resistance to many antimicrobial agents, has been identified in a variety of bacterial 
species, and a number of efflux pump determinants have been sequenced and cloned 
(Paulsen et al, 1996). There are five major families of efflux transporter in the 
prokaryotic kingdom: major facilitator (MF), multidrug and toxic efflux (MATE), 
resistance nodulation division (RND), small multidrug resistance (SMR), and ATP 
binding cassette (ABC) (Lomovskaya et al, 2001). Transporters that efflux multiple 
compounds, including antibiotics have not emerged in response to the antibiotic era. 
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It has been identified that 5% to 10% of all bacterial genes participate in transport 
and a large number of these encode efflux pumps (Saier & Paulsen, 2001), indicating 
that they must have preceded the antibiotic era.  
 
There is a relation between resistance to bacteria and increase in gene expression of 
efflux pumps; for example; resistance to bile salts and antibiotics in Escherichia coli 
is caused by over expression of acrAB (Thanassi et al, 1997). Although genes 
encoding efflux pumps may be present on plasmids, the carriage of efflux pump 
genes on the chromosome confers the bacterium an intrinsic mechanism that permits 
survival in a hostile environment, such as the presence of antibiotics. Therefore 
mutant bacteria that over-express efflux pump genes, raising the threshold of 
resistance, may be selected without the acquisition of any new genetic elements. 
Probably these pumps emerged so that toxic substances could be excreted out of the 
bacterium. It is now widely acknowledged that the intrinsic resistance of Gram 
negative bacteria to specific antibiotics, compared with Gram positive bacteria, is 
due to the activity of an efflux system (Li, Livermore & Nikaido, 1994). Efflux 
systems that confer antibiotic resistance to some bacteria, have been identified from a 
number of clinically significant bacteria, including Escherichia coli (AcrAB-TolC, 
AcrEF-TolC, EmrB, EmrD9) (Poole, 2000), Campylobacter jejuni (CmeABC) (Lin, 
et al, 2000), Pseudomonas aeruginosa (MexAB-OprM, MexCD-OprJ, MexEF-OprN 
and MexXY-OprM) (Poole, 2000), Staphylococcus aureus (NorA) (Kaatz and Seo, 
1995), Streptococcus pneumoniae (PmrA) (Gill et al, 1999), and Salmonella 
typhimurium (AcrB) (Nikaido, 2000). All of these efflux systems and the RND 
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pumps (CmeB, AcrB and the Mex pumps) also transport multiple antibiotics out of 
the bacterial cell membrane (Webber and Piddock, 2003).  
 
1.1.5.3.4. Enzyme production 
The most important mechanism of β-lactam resistance, especially amongst Gram 
negative bacteria, is the production of β-lactamases. These enzymes can hydrolyse 
β-lactam ring, resulting in the antimicrobial ineffective (Helfand & Bonomo, 2003). 
β-lactamase enzymes are structurally similar to PBPs (Massova and Mobashery, 
1998) and may have emerged from β-lactam binding enzymes of cell wall 
biosynthesis. They were first described in Escherichia coli isolates before the release 
of the first β-lactam drug, penicillin (Abraham & Chain, 1940). Since then, these 
enzymes have been identified in Gram negative and Gram positive bacteria  where 
they are found either chromosomally or plasmid encoded, and usually associated 
with mobile genetic structures such as transposons and integrons (Rowe-Magnus and 
Mazel, 2002). 
 
By 2009, the number of individual protein sequences for β-lactamases was more than 
890. β-lactamase enzymes production is most commonly suspected in Gram negative 
bacteria that exhibit resistance to a β-lactam antibiotic (Bush and Jacoby, 2010). 
Classification based on molecular structure was first suggested by Ambler (1980) 
with two classes. Class A included PC1 β-lactamases encoded by the chromsome of 
Staphylococcus aureus, with a serine residue at the active site, and class B metallo-
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β-lactamases including the type II enzyme encoded by Bacillus cereus, with Zn2+ at 
the active site. Jaurin and Grundstorm, (1981) identified class C cephalosporinases in 
Escherichia coli K12, with a serine residue at the active site. Class D β-lactamases 
were separated from other serine β-lactamases after sequencing of PSE-2 and OXA-1 
hydrolysing carbencillin and oxacillin (Houvinen et al, 1988). Many kinetic, 
mutagenesis and structural reports have been done on these enzymes, contributing 
significant information about their substrate specificities and catalytic mechanisms 
(Helfand & Bonomo, 2003). Some of these enzymes can target the expanded 
spectrum β-lactams such as the cephalosporins, including the extended spectrum β-
lactamases (ESBL) (classes A and D) (reviewed by Bradford, 2001), the AmpC 
(class C cephalosporinases) enzymes (Philippon, Arlet & Jacoby, 2002), and the 
carbapenemases that can hydrolyse most β-lactams agents, including the 
carbapenems (classes A, B and D) (Poirel & Nordmann, 2002).  
 
The Ambler molecular scheme was modified to one based on a combination of both 
functional and molecular schemes. According to both systems classification, there 
are groups 1, 2, and 3, and subgroups 2a, 2c, 3a, etc (Bush & Jacoby, 2010). Group1 
cephalosporinases which are not inhibited by clavulanate, group2 broad spectrum 
enzymes which comprise the largest category and are generally inhibited by 
clavulanate with the exception of the 2d and 2f sub-groups, and the group3 metallo-
β-lactamases. However, most ESBLs are allocated to group 2be which can hydrolyse 
penicillins, monobactams, and cephalosporins and inhibited by clavulanate according 
to the Ambler classification. The CTX-M enzymes fulfill the criteria for group 2be 
enzymes (Dhillon and Clark, 2012) Table 1.1. 
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class Main substrate 
Inhibited by Representative 
enzymes CA/TZB EDTA 





1e C Cephalosporins - - GC-1, CMY-
37 
2a A Penicillins + - PC1 
2b A Penicillins, early 
cephalosporins 
+ - TEM-1, TEM-
2, 
SHV-1 
2be A Extended-spectrum 
cephalosporins, 
monobactams 
- - TEM-3, SHV-
2, CTXMs, 
PER, VEB 
2br A penicillins - - TEM-30, SHV-
10 
2ber A Extended-spectrum 
cephalosporins, 
monobactams 
- - TEM-50 
2c A Carbencillin + - PSE-1, CARB-3 
2ce A Carbencillin, cefepime + - RTG-4 
2d D Cloxacillin V - OXA-1, OXA-10 
2de D Extended-spectrum 
cephalosporins 
V - OXA-11, OXA-
15 
2df D Carbapenems V - OXA-23, 0XA-
48 
2e A Extended-spectrum 
cephalosporins 
+ - CEPA 
2f A Carbapenems V - KPC-2, IMI-1, 
SME-1 
3a (B1) B Carbapenems - + IMP-1, VIM-1, 
IND- 
1, CcrA 
 (B2)    L1, CAU-1, 
GOB-1, 
FEZ-1 
3b (B3) B Carbapenems - + CphA, Sfh-1 
4 Unknown -    




1.1.6. The clinically important β-lactamases 
In the last fifty years, β-lactamases have attracted much attention owing of their 
clinical relevance. Actually, they have been admitted to be responsible for a large 
case number of therapeutic failures. During the early 1960s, TEM-1 was the first 
plasmid-mediated β-lactamase in Europe and was obtained from Escherichia coli 
(Datta et al, 1965). Since then there has been global spread of the TEM-1 genetic 
structure to other bacterial species (Pseudomonas aeruginosa, Haemophilus 
influenza, Neisseria gonorhoeae) to the extent that it has become the most common 
resistance gene of all (reviewed by Bradford, 2001). At the same time, the SHV-1 β-
lactamase was identified to be encoded by the chromosome of Klebsiella 
pneumoniae (Pitton, 1972) and then subsequently was identified as a plasmid 
encoded enzyme in Escherichia coli (Nugent & Hedges, 1979) 
 
Escherichia coli possessing plasmid encoded TEM-1 and SHV-1 β-lactamases 
appeared after the introduction of the amidopenicillins such as ampicillin and 
amoxycillin. Cephalosporins were introduced to overcome this plasmid mediated 
resistance. The introduction, particularly of the oxyimino-cephalosporins, into the 
health market, did overcome this resistance for some time. However, mutations 
started to emerge in TEM-1 and SHV-1 β-lactamases, giving rise to the so-called 
extended spectrum β-lactamases (ESBLs). The first that was activaely reported was 
the SHV-2 β-lactamase, detected in a strain Klebsiella pneumoniae in Germany 
(Kliebe et al, 1985). These new types of enzymes can destroy third generation β-
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lactams (called ESBLs) and are continuously growing particularly in Europe and 
Asia (Rupp & Fey, 2003; Bradford, 2001; ZEBA, 2005). 
 
1.1.6.1. Class A β-lactamases 
Generally, class A β-lactamase enzymes are susceptible to β-lactamase inhibitors 
such as clavulanate, tazobactam and, to a lesser extent, sulbactam. However the 
Klebsiella pneumoniae carbapenemase KPC may be an exception to this 
generalization (Papp-Wallace et al, 2009). The first plasmid mediated member of this 
class was described in Escherichia coli in 1963, and was named TEM (Datta, & 
Kontomichalou, 1965). SHV which is another common β-lactamase detected 
primarily in Klebsiella pneumoniae (Matthew et al, 1979). TEM and SHV are 
common β-lactamases described in clinical isolates of Escherichia coli and 
Klebsiella pneumoniae, primarily responsible for urinary tract, bloodstream, and 
hospital-acquired respiratory tract infections (Buynak, 2006). Although SHV-1 and 
TEM-1 share about 68% sequence similarity, the active site of SHV-1 is 
approximately 0.7 to 1.2 Å wider than TEM-1, which gives significant structural 
implications, particularly associated to the substrate profiles of SHV variants 
(Tzouvelekis & Bonomo, 1999). blaTEM and blaSHV  may be detected on plasmids 
but other class A β-lactamases are encoded on the chromosome such as blaPenA from 
Burkholderia pseudomallei, or on integrons such blaVEB-1 in Pseudomonas 
aeruginosa and Acinobacter baumannii, and blaGES-1 from Klebsiella pneumoniae 
(Naas et al, 2008).  
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1.1.6.1.1. Extended spectrum β-lactamases (ESBL) families 
ESBLs are primarily found in the Enterobacteriaceae family of Gram negative 
bacteria, particularly Escherichia coli and Klebsiella pneumoniae (Paterson and 
Bonomo, 2005). These enzymes are also produced by non-fermentative Gram 
negative bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii 
(Jacoby & Munoz-Price, 2005). ESBLs are plasmid-mediated enzymes and can 
hydrolyse oxyimino-cephalosporins, and monobactams but not cephamycins or 
carbapenems (Bradford, 2001). Also these enzymes, like their parent enzymes, are 
inhibited in vitro by clavulanate (Paterson & Bonomo, 2005). There are several 
ESBLs genotypes. The most common of these are the SHV, TEM, and CTX-M 
(Rupp and Fey, 2003). But also there are other clinically important genotypes include 
VEB, PER, BES-1, BEL-1, SFO-1, TLA, and IBC (reviewed by Jacoby & Munoz-
Price, 2005). 
 
According to the Bush and Jacoby scheme (Table 1.1) (Bush & Jacoby, 2010) 
ESBLs enzymes can be divided into three main groups: group1 cephalosporinases 
which are not inhibited by clavulanate, group 2 broad spectrum enzymes which 
comprise the largest group and are generally inhibited by clavulanate except the 2d 
and 2f groups, and the group3 metallo-β-lactamases. However, most ESBLs are 
allocated to group 2be which can hydrolyse penicillins, monobactams, and 
cephalosporins and are inhibited by clavulanate, they are class A according to the 
Ambler molecular scheme. CTX-M genotype still suits the former criteria for group 




When ESBLs were first identified in the early 1980s, they were shown to be point 
mutations of the TEM and SHV broad spectrum β-lactamase enzymes, which lead to 
cephalosporin resistance (Kliebe et al, 1985). The mutations in the genes caused 
these enzymes to have high catalytic activities for β-lactams by lowering the Km 
values (increasing the affinity) for the β-lactams (Knott-Hunziker et al, 1982). They 
have emerged to be a major cause of hospital acquired infections, especially in 
intensive care unit (Falagas and Karageorgopoulos, 2009). TEM and SHV have been 
identified worldwide and are described as giving resistance to extended spectrum 
cephalosporins. The heavy use of such antibiotic has been described as the reason of 
this resistance (Livermore & Hawkey, 2005). Since the beginning of the 21st century, 
it has become significantly apparent that a shift in the genotypic structure of ESBLs 
is taking place (Dhillon & Clark, 2012).  
 
The CTX-M genotype, deriving from chromosomally encoded β-lactamase enzymes 
of the Kluyvera spp, has increased radically, particularly in Escherichia coli and 
Klebsiella pneumoniae ((Livermore & Hawkey, 2005). It is thought that the genes 
were inserted into plasmids then transferred to pathogenic bacteria, with the ability to 
move on among different bacterial species and genera (Bonnet, 2004). There are 
more than 50 variants of CTX-M so far, and they have been linked to numerous 
outbreaks of infections either in hospitals or in the community, especially in urinary 
Escherichia coli isolates in nonhospital settings (Dhillon & Clark, 2012; Falagas and 
Karageorgopoulos, 2009). Studies from different countries showed that once a CTX-
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M β-lactamase penetrates a certain geographic area it becomes predominant with 
displacement of TEM and ESBL variants (Bonnet, 2004; Livermore and Hawkey, 
2005). 
 
1.1.6.1.1.1. TEM β-lactamases 
The TEM family of ESBLs represents the largest and widely disributed group among 
these enzymes. TEM-1 and TEM-2 penicillinases are their evolutionary precursors 
(Livermore, 1995; Medeiros, 1997; Bradford, 2001). They hydrolyse the β-lactam 
ring of penicillins, cephalosporins, and related antibiotics and are detected at high 
rates in hospitals and clinics worldwide (Matagne et al, 1998). TEM-1 was the first 
TEM allele described and isolated from penicillin resistant E. coli in 1963 (Datta and 
Kontomichalou, 1965). The emergence in the 1980s of new cephalosporins such as 
ceftazidime and cefotaxime onto the market led to growing problems of β-lactamase-
producing organisms. This initiated the appearance of modified or new β-lactamases 
giving resistance to these antibiotics (reviewed by Bradford, 2001). 
 
More than 200 TEM (http://www.lahey.org/Studies/temtable.asp) variants have been 
identified by now and new genes continue to appear. These TEM variants alter in 
amino acid sequence by one to five substitutions and many of them alter in resistance 
phenotype (i.e. the degree of resistance they give to different antibiotics). Although 
TEM-1 only gives resistance to penicillins and early cephalosporins, the resistance of 
its derivatives has surpassed second-, third-, and fourth-generation cephalosporins, β-
lactamase inhibitors, and monobactams (Merijn et al, 2010). TEM-2 was the first 
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derivative of TEM-1 and had a single amino acid substitution at position 39; 
however, this did not change the substrate profile although it did change the 
isoelectric point from 5.4 in TEM-1 to 5.6 in TEM-2. TEM-3 was the first TEM-type 
β-lactamase that revealed the ESBL phenotype (Sougakoff et al, 1988; Payne & 
Amyes, 1991; Du Bois et al, 1995).  
 
The amino acid substitutions that are found within the exteneded-spectrum TEM 
enzymes concentrate at a limited number of amino acid positions. A few amino acid 
residues substitutions are particularly significant for producing the ESBL 
phenotype.The pivotal change is the substitution of arginine164 by either serine or, 
less commonly, histidine. Arginine 164 forms two ionic bonds with glutamate171 
and asparate 179. The substitution of arginine removes those bonds and the small α-7 
helix at the entrance of the active site moves to one side allowing the larger 
cephalosporins to bind and raising the MIC of ceftazidime to around 4mg/L (Du Bois 
et al, 1995).  
 
Following initial substitution at position 164, additional substitutions further increase 
the MIC of ceftazidime.These changes include glutamate to lysine at position 104 
and glutamate to lysine at position 240, which can raise the MIC of ceftazdime to 
around 64mg/L (Du Bois et al, 1995; Perilli et al, 1997). A different set of 
substitutions starting with glycine to serine at position 238, raises the MIC of 




TEM-type β-lactamases are most frequently identified in Escherichia coli and 
Klebsiella pneumoniae, but they are also described in other species of Gram negative 
bacteria (Bradford, 2001). TEM-type ESBLs have been identified in non 
Enterobacteriaceae Gram negative bacteria such as Pseudomonas aeruginosa (TEM-
42) (Mugnier et al, 1996). 
 
1.1.6.1.1.2. SHV β-lactamases 
SHV-1 is a narrow spectrum β-lactamases enzyme with activity against penicillins 
(Matthew et al, 1979). This enzyme first identified as a chromosomally encoded β-
lactamase in Klebsiella species (Nugent & Hedges, 1979). In addition, SHV-1 
enzyme is most frequently detected in Klebsiella pneumoniae and is responsible for 
about 20% of plasmid-mediated ampicillin resistance in the latter species 
(Tzouvelekis & Bonomo, 1999). Several studies showed that the SHV-1 β-lactamase 
gene is encoded by a transposon and it has been observed on plasmids of different 
types (Nugent & Hedges, 1979), but the observations of the physical transfer of the 
blaSHV by transposition has never been proven (Jacoby & Sutton, 1991).  
 
The first emergence of an SHV ESBL was reported in Germany (Knothe et al, 1983), 
which was called SHV-2. There are relatively few SHV-1 variants comparing to 
TEM-type β-lactamases (http://www.lahey.org/Studies/). The changes that have been 
seen in blaSHV result in appearance of different SHV derivatives exhibit in fewer 
positions within the gene. Because of its similarity to SHV-1 the new variant was 
called SHV-2 (Kliebe et al, 1985). A single amino acid substitution changes the 
spectrum of activity of the SHV-1 β-lactamase to include extended-spectrum 
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cephalosporins. Glycine at position 238 in SHV-1 is substited by serine in SHV-2 
(Barthélémy et al, 1988). Most of SHV variants expressing an ESBL phenotype are 
specified by changing of a serine for glycine at position 238, which increases the 
resistance to cefotaxime. A further substitution at position 240 of lysine for 
glutamate to give SHV-5 increases the hydrolysis of ceftazidime (Du Bois et al, 
1995). It is interesting to know that both Gly238Ser and Glu240Lys amino acid 
changes are similar to those seen in TEM-type ESBLs and perform the same 
functional changes (Huletsky, Knox, and Levesque. 1993). 
 
Nowadays, most of SHV-type variants express the ESBL phenotype. However, 
SHV-10 is described to have an inhibitor-resistant phenotype. This variant occurs to 
be derived from SHV-5 and have one additional amino acid substitution at position 
130 of glycine for serine (Prinarakis et al, 1997). In addition, most of SHV-type 
ESBLs are detected in Klebsiella pneumoniae (Bradford et al, 1997). However, these 
enzymes have also been detected in strain of Escherichia coli (Rasheed et al, 1997), 
Pseudomonas aeruginosa (Naas et al, 1999), and Citrobacter diversus (El Harrif-
Heraud et al, 1997). 
 
1.1.6.1.1.3. CTX-M β-lactamases 
The CTX-M type β-lactamases was identified as a new ESBL family member in 
1998 (Bonnet, 2004). The new type did not belong to either the TEM or SHV types 
though had the characteristics of a class A β-lactamase (Bauernfeind et al, 1990). 
The origin of CTX-M-type ESBLs was completely different from that of TEM- or 
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SHV-type ESBL (Bonnet, 2004). The CTX-M family of enzymes occurs to have 
derived from initial transfer of the chromosomal β-lactamase gene from Kluyvera 
spp. to conjugative plasmids that have readily dessiminate among different members 
of the Enterobacteriaceae and other gram-negative bacteria (Canton & Coque, 
2006). By the end of the 1990s, the majority of the ESBLs found were either TEM or 
SHV types which were often related to nosocomial outbreaks caused by Klebsiella 
pneumoniae (Paterson & Bonomo, 2005). The worldwide dissemination of CTX-M-
producing Escherichia coli has been increasing, and they are now known to be the 
main ESBL producers and are usually related to community-acquired infections 
(Pitout & Laupland, 2008).  
 
Unlike other ESBLs types, CTX-M family includes a complex and non-similar group 
of enzymes. The first analysis and alignment of the amino acid sequences of the 
CTX-M variants categorised these enzymes into five clusters (CTX-M-1, CTX-M-2, 
CTX-M-8, CTX-M-9, and CTX-M-25) (Bonnet, 2004) (Figure 1.5), but recent 
studies revealed that there are at least two more clusters (Rossolini et al, 2008). The 
phylogenetic analysis of the genes shows that the five main clusters of CTX-M 
enzymes exhibit >94% identity with other members of the same group, while there 
was ≤90% between members of different groups (Bonnet, 2004). The CTX-M-1 
group contains six plasmid-mediated enzymes CTX-M-1(Barthe´le´my et al, 1992), 
CTX-M-3 (Gniadkowski et al, 1998), CTX-M-10 (Karim et al, 2001), CTX-M-12 
(Kariuki et al, 2001), CTX-M-15 (Matsumoto et al, 1988), and FEC-1 (Oliver et al, 
2001)). The CTX-M-2 group contains eight plasmid-mediated CTX-M enzymes 
(CTX-M-2 (Bauernfeind et al, 1996), CTX-M-4, CTX-M-4L (Gazouli et al, 1998), 
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CTXM-5 (Bradford et al, 1998), CTX-M-6 (Gazouli et al, 1998), CTX-M-7 (Ishii et 
al, 1995), CTX-M-20 (Saladin et al, 2002), and Toho-1 (Tassios et al, 1999). The 
CTX-M-8 group contains one plasmid-mediated member (Bonnet et al, 2000). The 
CTX-M-9 group contains nine plasmid-mediated enzymes (CTX-M-9 (Sabate´ et al, 
2000), CTX-M-13, CTX-M-14 (Chanawong et al, 2002), CTX-M-16 (Bonnet et al, 
2001), CTX-M-17 (Cao et al, 2002), CTX-M-19, CTX-M-21, CTX-M-27 (Bonnet et 
al, 2003), and Toho-2 (Labia, 1999). To date, CTX-M variants exceed 135 enzymes 
(http://www.lahey.org/Studies). Phylogenetic analysis indicated that CTX-M β-
lactamases emerged not by mutations from earlier plasmid mediated enzymes but by 
mobilization of chromosomal bla genes from Kluyvera species. These bacteria are 
closely related to Escherichia coli and found worldwide (Canton and Coque, 2006). 
The bla genes were integrated into mobile genetic structures and transferred 
presumably by conjugation into clinical bacteria (Canton et al, 2008). These 
mobilized blaCTX-M genes increase cefotaxime resistance to a much greater degree 





Figure 1.5: Phylogeny tree of CTX-M family show every group of CTX-M with its 
types accordingly (adapted from Ruppé, 2010). 
 
The reasons why CTX-M enzymes have had the opportunity to increase the 
hydrolytic activity against ceftazidime in the new variants are probably because they 
have (i) diverge by mutations as consequence of antibiotic selective pressure on 
Kluyvera species. (ii) incorporated of blaCTX-M genes into mobile genetic elements 




Reports over the last 10 years revealed that with some exceptions, the CTX-M have 
nearly replaced other ESBLs enzymes in Enterobacteriaceae, involving TEM and 
SHV ESBL variants (Cantón, 2008; Coque et al, 2008). This replacement might have 
appeared not only as a result of the extraordinary spread of the corresponding blaCTX-
M genes in mobile genetic structures, including transposons and plasmids, but also 
because of the presence of these structures within successful clones (Cantón & 
Coque; Rogers et al, 2011). Another reason for this rise may be the co-
resistancephenomenon in CTX-M producing isolates, especially to aminoglycosides 
and fluoruquinolones, which can facilitate co-selection process (Cantón and Ruiz-
Garbajosa, 2011).  
The presence of co-resistance gives advantages to the bacteria under selective forces 
of antibiotics. It is known that the emergence of antibiotic resistance is a direct result 
of the consumption of the antibiotics and that resistance is appeared by mutational 
events in a Darwinian way (Sykes, 2010). However, selection does not only include 
mutations but also resistance genes transferred by horizontal transfer (Canton & 
Morosini, 2011). The pre-existence of resistance genes in the nature that might be 
captured and inserted in the bacterial genome resulting in resistance phenotypes is 
widely known (Canton, 2009).   
 
The significance of plasmids in the dissemination of blaCTX-M genes can be seen with 
specific CTX-M β-lactamases and has been reported in several studies (Carattoli, 
2009). For example, blaCTX-M-15 genes are mostly associated with plasmids of 
incompatibility group FII (Coque et al, 2008). They are characterized by own copy 
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number in the bacteria. These genes are also detected in Enterobacteriaceae and have 
previously been named as epidemic resistance plasmids because of their ability to 
acquire and transfer resistance genes among bacteria (Carattoli, 2009). Within the FII 
plasmids, different replicon types may be present that could facilitate quick evolution 
and plasmid diversification. In addition, studies on IncFII plasmids proposed that 
they were excessively disseminated within Enterobacteriaceae, even before antibiotic 
use, and fully adapted to these bacteria (Datta et al, 1980). This may have facilitated 
the existence and dissemination of resistance genes after acquisition, including 
blaCTX-M genes. Furthermore, linkage of these genetic determinants to genes 
mediating non-β-lactam resistance mechanisms might have also provided the key to 
the maintenance of these plasmids within the organisms and thus the blaCTX-M genes 
under co-selection process (Woodford et al, 2009). 
 
Other broad host range replicon plasmids like IncN, IncI1, and IncL/M have also 
been included in the spread and dissemination of CTX-M enzymes. Some of these 
plasmids, such as IncN, could have their reservoir in animals and have been isolated 
extensively in Escherichia coli and Salmonella species isolated from food producing 
animals (Carattoli, 2011). These plasmid usually carry qnr or aac(6)-Ibcr genes 
giving low level fluoroquinolone resistance (Bado et al, 2010). Recently, these 
plasmids have been shown to be able to harbour genes coding the emerging 
carbapenemase like blaNDM-1 (Poirel et al, 2011) and have been described as epidemic 
plasmids in different countries with a predominance of carbapenem resistance 




The IncL/M group of plasmids have the ability to carry blaCTX-M genes, such as 
blaCTX-M-3 and blaCTX-M-15 (Sabtcheva et al, 2008). Other types of plasmids such as 
IncK plasmid have been associated with blaCTX-M-14 in southern Europe (Cottel et al, 
2011), this incompatibility group has also been associated with the dissemination of 
blaCMY genes (Baudry et al, 2009). The IncH12 plasmids have been associated with 
the spread of the blaCTX-M-2 and blaCTX-M-9 in other geographical regions (García-
Fernández et al, 2007) and it has also been linked with the dissemination of blaVIM 
and qnr genes (Oteo et al, 2010b) These studies indicate the ability of individual 
plasmid groups to recruit resistance genes, thus enhancing the persistence and 
prevalence of these resistance genes in bacteria. Moreover, it is proposed that 
persistence for along time also provides the opportunity to create gene variation and 
thus an increasing number of blaCTX-M variants to deal with all cephapsporin types. 
This is similar to what has happened with the OXA-type β-lactamases (Evans, 
Hamouda & Amyes, 2007). Some of these blaCTX-M variants have been recovered in 
vitro under selective pressure of antibiotics but have not yet been detected in clinical 
isolates (Ripoll et al, 2011). 
 
One of the important issues in the dissemination of CTX-M enzymes is the 
participation of certain clones of inidivdual bacterial species, especially those from 
Escherichia coli and Klebsiella pneumoniae. In addition, it has suggested that despite 
a high diversity of CTX-M producers, a few clones or sequence types clustered in 
clonal complexes have been frequently associated with CTX-M enzymes. This 
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denotes that these clones are involved in the spread of these enzymes and that the 
success of specific CTX-M enzymes might also rely on certain sequence types or 
clonal complexes where they are repeatedly exist (Woodford et al, 2011). The 
presence of high risk clones in the nature increases the chance of accumulating 
resistance genes. In Gram negative bacteria, the ST131 E. coli was identified 
worldwide as carrying the blaCTX-M-15 gene, which encodes the successful ESBL 
(Cantón & Ruiz-Garbajosa, 2011). 
 
A connection between blaCTX-M genes and certain surrounding genetic components, 
including Insertion sequences, integrons, and transposons has been identified. These 
genetic elements are incorporated into more complex structures; for example 
different plasmid replicon types and certain clones giving a complex hierarchical 
organization with the opportunity of exchanging different modules (Carattoli, 2011; 
Woodford et al, 2011). blaCTX-M genes have been theoretically mobilized from 
Kluyvera species by insertion sequences or by lesser extent bacteriophages. The 
insertion sequence plays a role in the over-expression of blaCTX-M genes and some of 
these such as ISCR1 are joined to integron structures that are also joined to 
transposition units (Baquero, 2004; Cantón & Ruiz-Garbajosa, 2011). In addition, 
these structures are usually integrated within conjugative plasmids that might be 
included in successful clones. Their presence in the successful clones has been 
suggested to be crucial to the evolutionary success of the bacteiral clone (Baquero, 
2004; Canton and Ruiz-Garbajosa, 2011). Some of these structures and plasmids, 
which harbour blaCTX-M genes, also carry other resistance genes, including genes 
encoding carabapenemases and AmpC β-lactamases (plasmid blaAmpC), methylases 
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affecting aminoglycosides, or plasmid-mediated quinolone resistance genes (qnr 
genes). All these genes could also confer an advantage for the maintenance of blaCTX-
M genes because of co-selection pressure (Cantón et al, 2012).  
 
There are several studies identifying new or unique genetic rearrangement linked to 
blaCTX-M genes but further analysis showed that these are only variations of a small 
number of different genetic structures (Lartique et al, 2004, Eckert et al, 2006, 
Dhanji et al, 2011).  The mobilization of blaCTX-Ms genes has been by insertion 
sequences placed astride the gene. Furthermore, in the insertion sequence upstream 
of the gene, there is often a promoter enhancing blaCTX-M expression. So the insertion 
sequence upstream of blaCTX-Ms genes has a role both in the selection and spread of 
these genes. The downstream sequences of blaCTX-M genes are more variable and 
there is less information about them. (Cantón et al, 2012).  
 
Many different insertion sequences have been described upstream of blaCTX-Ms genes, 
including ISEcp1, ISCR1, IS10, and IS26 (Eckert et al, 2006; Bae et al, 2008). 
ISEcp1 is the most frequently insertion sequence detected upstream of different 
blaCTX-M genes. Although it was first reported linked to the blaCTX-M-15 gene in 1999, 
it has been associated with all groups of these β-lactamases except blaCTX-M-8. In 
addition, IS10 has been associated with blaCTX-M-8 and ISCR1 with several members 
of blaCTX-M-2 and blaCTX-M-9 clusters. The number of new genetic environments 
upstream of blaCTX-M can be associated with the number of mobilizations. A new 
insertion sequence can interupt an insertion sequence already present upstream of 
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blaCTX-M; for example, IS1, IS10, ISCR1, and IS26 have been shown to be capable of 
inserting into ISEcp1 (Eckert et al, 2006; Bae et al, 2008). To date, there have been 
descriptions of at least nine mobilization situations: three in CTX-M-1 cluster 
(blaCTX-M-10, blaCTX-M-53, and other common blaCTX-M genes included in this group), 
two in CTX-M-2cluster (blaCTX-M-2 and blaCTX-M-5), one in CTX-M-8 and CTX-M-25 
(blaCTX-M-8 and blaCTX-M-25, respectively), and two in CTX-M-9 cluster (blaCTX-M-9 
and blaCTX-M-14) (Cantón et al, 2012).  
Spacer sequences between the genes of ISEcp1 and blaCTX-M have been well 
described. The genetic distance between insertion sequence and blaCTX-M gene has 
been associated with the level cephalosporin MIC values (Ma et al, 2011). These 
genetic distances range from 48 to 127 bp in the  blaCTX-M-1 gene cluster, about 34 to 
42 bp in blaCTX-M-9 gene cluster and around 40 to 52 bp in blaCTX-M-25 and blaCTX-M-8 
gene clusters respectively. When the similarity among spacer sequences of blaCTX-M-1 
gene cluster was examined, most contained a common region with some minor 
exceptions such as those found with blaCTX-M-10 and blaCTX-M-53. This denotes that the 
blaCTX-M genes belonging to the blaCTX-M-1 cluster might have originated from a single 
transposition event. In these clusters, the source was Kluyvera georgiana. However, 
the absence of homology in spacer sequences of these blaCTX-M gene clusters denotes 
a different source for each one. These results demonstrate that a Kluyvera species, 
which has not been described so far, might be the source of clusters currently 




It is admitted that chromosomal blaKlu genes are poorly expressed in the original 
strain and need the presence of a strong promoter upstream to enhance the MIC 
values, leading to phenotypic resistant isolates Although the capture of ISEcp1 
upstream of chromosomal blaklu/CTX-M genes appears at a high rate in laboratory 
settings, these insertion sequences have not been identified in natural isolates of 
Kluyvera (Lartigue et al, 2006). When ISEcp1 was integrated upstream of blaKlu/CTX-
M gene, a stress situation, such as that imposed by the antibiotics cefotaxime or 
ceftazidime, enhances the mobilization of ISEcp1 and the transfer of the blaKlu/CTX-M 
gene (Lartigue et al, 2006; Nordmann et al, 2008). 
 
1.1.6.1.1.4. Other ESBLs enzymes 
Whereas the majority of ESBLs are coming from TEM or SHV β-lactamases and 
others might be classified with one of the newer families of ESBLs, several ESBLs 
have been described that are not closely related to the well-known families of β-
lactamases (reviewed by Bradford, 2001).  
 
PER-1 was first reported in Pseudomonas aeruginosa (Nordmann et al, 1993), and 
later found in Salmonella enterica (Gierczynski et al, 2003), Klebsiella pneumoniae 
(Paterson et al, 2003), Acinetobacter baumannii (Yong et al, 2003) and Proteus 
mirabilis (Pagani et al, 2002). PER-2 has been found in Salmonella enterica 
(Bradford, 2001), Enterobacter species (Quinteros et al, 2003), Klebsiella 
pneumoniae (Melano et al, 2003), and Vibrio cholerae (Petroni et al, 2002). There 
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have subsequently been a number of new PER enzymes found (Opazo et al, 2012). 
VEB-1 has been detected in Escherichia coli, Proteus mirabilis, Klebsiella 
pneumoniae (Cao et al, 2002), Pseudomonas aeruginosa (Chanawong et al, 2001), 
and Enterobacter species (Girlich et al, 2001). All of these enzymes preferentially 
hydrolyse and enhance resistance to both ceftazidime and aztreonam (Poole, 2004). 
The CME-1 and TLA-21 ESBLs found in Chryseobacterium meningospeticum and 
Escherichia coli, respectively (reviewed by Bradford, 2001). Other uncommon 
ESBL enzymes include the BES-1 enzyme found in Salmonella marcescens (Bonnet 
et al, 2000), the SFO-1 enzyme in Enterobacter cloacae (Matsumoto & Inoue, 
1999), The FEC-1 enzyme observed in Escherichia coli (reviewed by Bradford, 
2001), the IBC-1 enzyme detected in Enterobacter cloacae (Giakkoupi et al, 2000), 
the GES-1 enzyme found in Klebsiella pneumonia (Correia et al, 2003). 
 
1.1.6.1.2. Class A carbapenemases 
Serine carbapenemases class A β-lactamases, of functional group 2f, have occurred 
infrequently since their first detection in 1986 (Medeiros & Hare, 1986). These β-
lactamases have been described in members of the Enterobacteriaceae, especially 
Klebsiella pneumoniae, and Serratia marcescens in small outbreaks and in single 
isolates (Medeiros & Hare, 1986; Nordmann, 1993; Yang, Wu & Livermore, 1990). 
Isolates exhibiting these enzymes are known by reduced imipenem susceptibility, but 
MICs range from intermediate (i.e. imipenem MICs of ≤4 µg/ml) to fully resistant. 
Therefore, carbapenemase enzymes might be difficult to recognise when using 




Three main families of class A serine carbapenemases have been described, which 
include KPC, NMC/IMI, and SME enzymes. Their hydrolytic activity requires an 
active site serine at position 70 (Ambler et al, 1991). All these enzymes have the 
ability to hydrolyze a wide variety of β-lactams, including penicillin, cephalosporins, 
aztreonam as well as carbapenems, however all are inhibited by tazobactam and 
clavulanate, locating them in the group 2f functional subgroup of β-lactamases. The 
GES β-lactamases, which was classified as ESBL family, but then variants were 
detected that had low measurable imipenem hydrolysis. Consequently, this subgroup 
of GES enzyme is also categorized as functional group 2f carbapenemases (Queenan 
and Bush, 2007).  
 
The major chromosomal encoded serine class carbapenemase enzymes are SME, 
NMC, and IMI. These enzymes are classified in group 2f β-lactamases according to 
Amber classification (Queenan and Bush, 2007). SME-1 enzyme was first found in 
England from Serratia marcescens in 1982 (Nass et al, 1994). Infections caused by 
SME-producing Serratia marcescens were detected as single cases or small clusters. 
The IMI and NMC-A β-lactamases have been found in rarely in clinical isolates of 
Enterobacter cloacae in France (Rasmussen and Bush, 1996), United States 
(Pottumarthy et al, 2003) and Argentina (Radice et al, 2004). The NMC-A and IMI-1 
β-lactamases have 97% amino acids similarity and are related to SME-1, with nearly 
70% amino acid similarity (Nass et al, 1994; Rasmussen and Bush, 1996). These β-
lactamases genes are all located chromosomally, with no evidence of location within 
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mobile structures (Aubron et al, 2005). These enzymes hydrolyse imipenem more 
efficiently than meropenem, and show poor hydrolysis of cefoxitin and extended 
spectrum cephalosporins (Mariotte-Boyer et al, 1996; Queenan et al, 2000; 
Rasmussen and Bush, 1996).  
 
These chromosomal carbapenemase β-lactamases might be induced in response to 
challenge by cefoxitin and imipenem. Sequencing of the upstream regions of 
NMC-A, IMI-1, and SME-1 identified the existence of a divergently transcribed gene 
linked to the LysR family of DNA binding transcriptional regulatory genes (Naas 
and Nordmann, 1994; Nass et al, 1994; Rasmussen and Bush, 1996). Deletions 
within the nmcR gene stopped the inducibility of NMC-A and decreased carbapenem 
MICs, confirming a role for this protein to enhance NMC-A expression (Naas and 
Nordmann, 1994). 
 
Two structures of NMC-A and a structure for SME-1 reveal that all structures and 
catalytic residues are similar to other class A β-lactamases (Mourey et al, 1998; 
Sougakoff et al, 2002; Swaren et al, 1998). In the NMC-A β-lactamases, the 
structure of the enzyme did not alter when the inhibitor was bound. In fact, the 
disulphide bond between position 69 and 238 which is located near the active site, is 
essential for hydrolytic activity, not only for imipenem hydrolysis, but also for the 
stabilization of the enzyme structure (Majiduddin, and Palzkill, 2003; Sougakoff et 
al, 2002). In the case of the SME-1 β-lactamases, the hydrolysis of imipenem could 
not be atrributed to individual residues of the SME-1 active site alone, multiple 
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residues influence the active site structure and therefore affect substrate specificity 
(Majiduddin & Palzkill, 2005). 
 
On the other hand, there are transferable plasmid-encoded class A carbapenem-
hydrolysing β-lactamases, which include KPC (for Klebsiella pneumoniae 
carbapenemase) and GES. The spectrum of hydrolysis of the KPC β-lactamases 
includes third generation cephalosporins (such as cefotaxime) as well as 
carbapenems. These β-lactamases are most frequently detected in Klebsiella 
pneumoniae but also have been identified in Enterobacter and Salmonella species 
(Bratu et al, 2005b; Hossain et al, 2004; Miriagou et al, 2003).  
 
The first member of the enzyme KPC family (KPC-1) was detected in a clinical 
isolate of Klebsiella pneumoniae from the United States in 1996 (Yigit et al, 2001). 
This isolate was resistant to all β-lactam drugs. The detection of KPC-1 was followed 
by the discovery of KPC-2 in 2003, resulting from a point mutation in KPC-1 
(Moland et al, 2003). The blaKPC-2-producing gene was also carried on a transferable 
plasmid. Both enzymes showed reduced susceptibility to imipenem (Moland et al, 
2003). Another single amino acid variant of KPC-2 produced KPC-3 which was 
identified in a strain isolated in 2000 in the Klebsiella pneumoniae outbreak in New 
York (Woodford et al, 2004). Analysis of the KPC-3 enzyme showed a profile 
similar to that of KPC-1 and KPC-2, with slight rise in ceftazidime hydrolysis (Alba 




KPC class of carbapenemases have undergone rapid spread from the United States e. 
Since the detection of KPC-2, it was quickly found in Colombia (Villegas et al, 
2006) and China (Wei et al, 2007). The of KPC-2 gene on a plasmid in Pseudomonas 
aeruginosa shows a disturbing development in the dissemination of these 
carbapenemases (Villegas et al, 2007). 
 
The conserved active sites of the KPC enzymes class A carbapenemases have amino 
acid identity of around 45% to the SME carbapenemases. These enzymes have 
conserved cysteine residues at positions 69 and 238 that form a similar disulphide 
bond to those in the SME and NMC/IMI enzymes. The KPC-2 β-lactamase structure 
shows characteristic conserved motifs, when compared to the carbapenemases such 
as SME-1 and NMC-A; and non-carbapenemases such as TEM-1 and SHV-1 (Ke et 
al, 2007). 
 
Among the functional group 2f carbapenemase enzymes, the KPC family has been 
more frequent to disseminate owing to its location on transferable plasmids, as it is 
most commonly detected in Klebsiella pneumoniae. It is extremely difficult to treat 
infections caused by this organism because of its propensity to be multidrug resistant 





1.1.6.1.3. Class C AmpC-type β-lactamases 
Class C β-lactamases (AmpC) are an important contributor to multiple resistance of 
β-lactam antibiotics in Gram-negative bacteria, particularly the Enterobacteriaceae 
(Goossens, 2001; Garcia-Rodriguez and Jones, 2002). These enzymes were 
originally the chromsomal mediated enzymes of Gram-negative bacteria; however, 
the blaAmpC migrated onto plasmids from strains such as Citrobacter freundii 
(Woodford et al, 1990; Payne et al, 1992, Fosberry et al, 1994) and thus could be 
transported into Esherichia coli. They show activity against penicillins but are more 
active against oxyiminocephalosporins (cefotaxime, ceftazidime, and ceftriaxone). 
They can also hydrolyse cephamycins (cefoxitin and cefotetan) and monobactams 
(aztreonam), but are susceptible to carbapenems (and fourth generation 
cephalosporins (cefepime and cefprome) (Coudron et al, 2003). According to the 
Ambler structural classification, AmpC β-lactamases belong to class C, according to 
the functional classification they were placed in group 1 (Bush et al, 1995). 
 
Genes encoding enzymes of AmpC are located on the chromosomes of some 
Enterobacteriaceae (Walther-Rasmussen, and Hoiby, 2002; Stock et al, 2003; Stock 
and Wiedemann, 2003) and other Gram negative bacteria such as Pseudomonas 
aeruginosa (Walther-Rasmussen, and Hoiby, 2002), and Acinobacter baumannii 
(Nadjar et al, 2001). With the exception of Escherichia coli, these enzymes are 
inducible by some of β-lactam antibiotics. Although carbapenems are good inducers 
of these enzymes, their stability and prompt bactericidal activity to hydrolysis 




Chromosomal ampC genes expression is typically effected by the AmpR regulator 
and the ampD-encoded amidase which act negatively on ampC expression (Hanson 
and Sanders, 1999). AmpC-mediated resistance typically appears from mutational 
ampC gene expression, usually due to mutations in ampR and or ampD (Hanson and 
Sanders, 1999; Petrosino et al, 2002; Bagge et al, 2002). Recent studies on AmpC-
mediated β-lactam resistance reveal that ampC overexpression might appear as a 
result of upstream insertion of insertion sequences (Corvec et al, 2003; Segal et al, 
2004). 
 
Plasmid-encoded AmpC β-lactamases have now become increasing significant as as 
a mechanism of resistance to expanded-spectrum β-lactams. Klebsiella pneumoniae 
(Steward et al, 2001) and Escherichia coli (Philippon et al, 2002) often harbour these 
enzymes. Most plasmids harbouring ampC genes are not inducible due to the lack of 
ampR regulatiry gene. The overproduction of the plasmid blaAmpC is under the 
control of plasmid-encoded promoter in resistant bacteria (Reisbig et al, 2003). Many 
of the plasmid-borne blaAmpC genes are associated with integrons and transposable 
structures, so unlike plasmid-borne β-lactamase enzymes of classes A, B, and D, they 
are not included in characteristic gene cassettes. AmpC plasmids might harbour 
additional resistance genes for non-β-lactam antibiotics (Rodriguez-Martinez et al, 
2003; Zhao et al, 2003). Plasmid-borne AmpC β-lactamases are classified into five 




1.1.6.1.4. Class D OXA-type- β-lactamases 
The OXA-type β-lactamases belong to class D group according to Ambler 
classification, and are frequently found in Pseudomonas aruginoasa, but also found 
less frequently in some Gram negative organisms such as Acinetobacter baumannii 
(Nass & Nordmann, 1999; Paterson & Bonomo, 2005; Pournaras et al, 2006). 
Currently, over 18 OXA extended spectrum β-lactamases have been described 
(http://www.lahey.org/Studies/). Initially, OXA β-lactamases were known for their 
high degree hydrolysis of oxacillin and cloxacillin, however most of them did not 
affect the carbapenem and extended spectrum cephalosporins (Nass and Nordmann, 
1999). OXA-45 variant gives resistance to the third generation cephalosporins, 
aztreonam, and a fourth generation cephalosporins, cefepime (Ibuka et al, 2003). 
Their existence in plasmids and transposons may ease their horizontal movement, 
although some of them have been located on chromosomes (Nass and Nordmann, 
1999; Walther-Rasmussen & Hoiby, 2006). OXA-type ESBLs typically harbour 
multiple mutations; for example, substitutions at Gly167 are responsible for 
resistance against ceftazidime in OXA-10-derived ESBLs (Majiduddin et al, 2002).  
The OXA β-lactamases are the chromosomal β-lactamases of Acinetobacter spp, 
which is probably the source of these genes. Because of their predisposition to cause 
carbapenem resistance the OXA β-lactamases are also the biggest source of 









1. To detect the spread of CTX-M-β-lactamases in clinical isolates of bacteria in St 
George’s Hospital London from where the strains were collected.  
2. To detect the resistance profiles of the collected isolates and determine MDR 
patterns.  
3. To detect the genotypic relatedness using PFGE among the collected isolates and 
possible spread of a certain clone.  
4. To detect the most common member of CTX-M family of enzymes.  














2.1. Sample collection and storage  
One hundred isolates of mixed species of Enterobacteriaceae were received from St 
George’s London hospital in March 2010. All isolates were inoculated onto MacConky 
agar (Oxoid) and then incubated 24h at 37⁰C. A single colony was added to the beads of 
Cryobank Sysytem (Mast Diagnostic, UK) to each vial for long term storage at -70⁰C 
following the manufacturer’s instructions. The isolates in this study included 50 
Escherichia coli, 12 Klebsiella pneuomoniae, 5 Klebsiella oxytoca, 7 Enterobacter 
cloacae, one Enterobacter aerogens, one Enterobacter spp., 12 Proteus mirabilis, one 
Proteus vulgaris, six Lactose fermenting coliform, two isolates Pantoea spp., one 
Morganella morgana, one isolate Hafnia alvei, and one Serratia marcescens as listed in 






Table 2.1: Total number of each Enterobacteriaceae species. 
Isolate species Number of isolates 
Escherichia coli 50 
Klebsiella spp 17 
Enterobacter spp 9 
Proteus spp 13 
Lactose Fermenting Coliform 6 
Pantoea spp 2 
Serratia marcescens 1 
Morganella morganii 1 




2.2. Chemicals, buffers, and media 
All chemicals used in this study were bought from Sigma-Aldrich Company (Poole, 
UK) Ltd unless otherwise stated. Also, media were purchased as powder from Oxoid 
(Basingstoke, UK) and then preparation was done with distilled water before 
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sterilization process. Normal saline was made with 0.85% NaCl and sterilized before 
use.  
 
2.3. Determination of minimum inhibitory concentrations (MICs) 
The isolates in this study were examined for their susceptibility to four different classes 
of antibiotics to observe their spectrum activity. The antibiotics, their classes and the 
breakpoints used in this study are listed in Table 2.2. The minimum inhibitory 
concentrations (MICs) were determined by double dilutions agar method according to 
the British Society for Antimicrobial Chemotherapy (BSAC) (Andrews, 2010). The 
breakpoints of these antibiotics were described by Andrews (2012). The control strains 
used in this study were Escherichia coli ATCC 25922, P. aeruginosa ATCC 27853, and 











Table 2.2: Antimicrobial agents name, class, breakpoint and manufacturer. 
Name of the 
antimicrobial 
agent 
Class of the 
antimicrobial  
agents 
 Antimicrobial agent breakpoint Manufacturer 
     
     




2 mg/L  Sigma-Aldrich  





8 mg/L  Sigma-Aldrich  




4 mg/L  Sigma-Aldrich  




1 mg/L  (Bayer AG, 
Germany)  
Gentamicin  Aminoglycoside   4 mg/L  Sigma-Aldrich  
Imipenem  Carbapenem   8 mg/L  (Merck Sharpe 
Dohme, Rahway, 







8 mg/L  






NJ, USA)  
 
2.4. Double disc synergy method 
Synergy between cefotaxime and clavulanate was detected by placing a disc of 
amoxicillin + clavulanate 20 + 10μg; up, cefotaxime 30μg; and down, ceftazidime 30μg 
. A clear-cut extension of the edge of the cefotaxime and ceftazidime inhibition zone 
toward the disc containing clavulanate (as shown in figure 3.1) was interpreted as 
synergy. The double-disc synergy test was considered positive when decreased 







2.5. 10X TAE buffer 
10X TAE was prepared by the following procedure (Biokeystone Co LLC, California, 
USA): 48.44g of Trizma base (Sigma), 3.72g of EDTA (Ethylenediaminetetraacetic 
acid) disodium salt dehydrate 99%, 11.4 ml glacial acetic acid. It was mixed well until 
each component had dissolved completely and the pH was adjusted to 8.0. The solution 
was made upt to a final volume of 1L with distilled water. It was diluted 1:10 ready for 
use.  
 
2.6. PCR reagents  
PCR reagent were prepared from Promega reagents (Promega, Southampton, UK), Go 
Taq DNA Polymerase (5u/µl). In 5x colourless or green buffer, MgCl2 solution (25mM) 
and deoxynucleoside triphosphates (dNTP) / PCR nucleotide mix (10mM each). 
Sterilized distilled water was used as the diluents.  
 
2.7. PCR reaction 
All PCR reactions, unless otherwise, stated were performed in 50 µl volumes in PCR 
tubes. The reaction mixture consisted of 1.5mM (2 µl) MgCl2, 0.1mM (1 µl) dNTPs, 1X 
reaction buffer (10 µl), 0.05 mM (0.5 µl) each primer, 1 µl template and 0.2 units of 




2.8. Screening of PCR products 
Agarose (1g) was added to 100 ml TAE buffer (40 mM Tris acetate, 20 mM acetic acid, 
1 mM EDTA, pH 8.0). The agarose was solubilized by heating in a microwave oven for 
about 10 minutes and then the mixture was left to cool to room temperature. Then, five 
µl of each PCR product samples were put in the gel alongside 5 µl of a suitable 
molecular weight marker; in each case this was applied after mixing with 1 µl loading 
buffer on a piece of parafilm. Each mixture was applied to a slot prepared in the gel 
using 10 µl micropipette. The electrophoresis gel was covered and the power supply 
was switched on and adjusted to 10 Volt/cm. For staining the gel was immersed in 3X 
staining solution of GelRed dye (Biotium, Hayward, USA). GelRed was prepared from 
a stock reagent of the 3X staining solution which was prepared with 45 ml sterile 
distilled water, 5 ml of (1 M) NaCl, and 15 µl of the stock solution and left at room 
temperature for storage and further use. After running, the gel was visualized in an Ultra 
Violet transilluminator Bio-Rad Gel Doc 2000 (Bio-Rad, Hemel Hempstead, UK).  
 
2.9. Purification of PCR product 
PCR products were purified either directly or by separation of the DNA fragments from 
1%TAE Agarose gel electrophoresis. The DNA band on the gel of the correct size was 
sliced out from the gel. The purification of DNA by both methods was performed using 
a Qiagen purification kit (Qiagen, Crawley, UK) following the manufacturer’s 




2.10. Determination of DNA concentration 
The concentration of the purified DNA and its purity was measured by UV absorbance 
at 260 and 280 nm. The concentration of DNA was determined by the OD260nm (1 
OD260nm = 50 µg/ml dsDNA or 33 µg/ml ssDNA). The purity was calculated with the 





2.11. Sequencing of genes 
The resulting PCR products were sequenced by the Sanger method using QIAquick 
PCR Purification Kit (Qiagen, Crawley, UK) and sequenced by ABI3730 capillary 
sequencer (Applied Biosystems, Warrington, UK). The DNA sequencing results were 
analysed by using BioEdit, Multalin, EXPASY, Basic Local Alignment Search Tool 
(BLAST). The results of sequencing were compared with the previous published genes 
sequences in an online website (http://www.ncbi.nih.gov/BLAST) and 
(http://www.lahey.org/studies/webt.stm). The sequencing alignment results and protein 
sequences were achieved by the Multialin website 
(http://www.toulouse.inra.fr/multalin.html).   
 
2.12. Phenotypic and molecular identification of ESBLs genes 
For ESBL screening, the strains in this study were identified phenotypically with agar 
double dilution method. Then, confirmation of ESBL-production was done by disc 
diffusion. The concept of this test is to examine the presence of ESBL enzymes (Jarlier 
et al, 1988). According to the British Society for Antimicrobial Chemotherapy (BSAC) 
disc susceptibility test, one disc containing co-amoxiclav 20+10 µg is placed in the 
centre of an Isosensitest (ISO) agar plate between ceftazidime 30 µg and cefotaxime 30 
µg discs. The former two discs are applied 25-30mm a part (Livermore & Williams, 
1996). The plate was incubated overnight at 37° C, and numbers of selected CTX-M 




2.13 CTX-M gene detection 
Multiplex PCR was performed for identification of CTX-M genes using specific 
primers designed for identifying known β-lactamase genes (Individually, CTX-M 
groups 1, 2, 9, and, together, groups 8 and 25). Multiplex PCR templates were prepared 
by boiling a dense bacterial suspension in sterile distilled water; one µl of the boiled cell 
suspension supernatant was used in the PCR reaction. Primer pairs and predicted 
amplicon sizes are listed in Table 2.3. Whereas, frequents of the genes of group 8 
(666bp) and 25 (327bp) were amplified with two specific forward primers and a shared 
reverse primers (Table 2.3) The latter two groups were developed and optimized 
empirically (Woodford et al, 2006).  
 
PCR amplifications were performed using Taq polymerase (Promega) (initial 
denaturation at 94°C for 5 min., 30 cycles of 94°C for 25s, 52°C for 40s and 72°C for 
50s, and a final elongation at 72°C for 6 minutes).  In addition, the resulting PCR 
products were analyzed in 1.5% agarose gel, using the following electrophoresis: 30 
minutes, 100V, TAE buffer 1X.Both ethidium bromide and GelRed staining were used 
for visualization amplified products under an UV light (Woodford et al, 2006). The 
preparation of 1X TAE buffer was done by diluting a stock 10XTAE buffer 1:10.  
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Table 2.3: Primers used for the detection of blaCTX-M genes. 
 
Name Primer Amplicon 
size (bp) 
CTX-M-1 group members  
 
F-5'-AAA AAT CAC TGC GCC AGT TC 
R-5’-AGC TTA TTC ATC GCC ACG TT 
415 
CTX-M-2 group members  
 
F-5'-CGA CGC TAC CCC TGC TAT T 
R-5'-CCA GCG TCA GAT TTT TCA GG 
552 
CTX-M-9 group members  
 
F-5'-CAA AGA GAG TGC AAC GGA 
R-TG 5'-ATT GGA GGT TCA TCA CC 
205 
CTX-M-8 group members  
 
F- 5'-TCG CGT TAA GCG GAT GATGC 





F-5'-GCA CGA TGA CAT TCG GG 




2.14 AmpC β-lactamase genes detection 
Multiplex PCR was performed for the detection of AmpC β-lactamase genes (Perez and 
Hanson, 2002), using specific primers for PCR amplifications. These primers are listed 
in Table 2.4. The PCR program combine of an initial denaturation at 94°C for 3 
minutes, 25 cycles of DNA denaturation at 94°C for 30 seconds, primer annealing at 
72°C for 1 minute. The last cycle was followed by a final extension at 72°C for 7 
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minutes. The PCR products were analyzed in 1.5% agarose gel, using the following 
electrophoresis conditions: 30 minutes, 100V, TAE buffer 1X. GelRed staining was 
used for visualization amplified products under an UV light. Negative controls were 
performed with water in place of template DNA.  
  
Table 2.4: Primers used for amplification of AmpC genes. Adapted from Perez & 
Hanson (2002).  




CMY-8 to CMY-11 
MOXMF GCT GCT CAA GGA GCA CAG GAT 520 
MOXMR CAC ATT GAC ATA GGT GTG GTG C 
LAT-1 to LAT-4, 
CMY-2 to CMY-7, 
BIL-1 
CITMF TGG CCA GAA CTG ACA GGC AAA 462 
CITMR TTT CTC CTG AAC GTG GCT GGC 
DHA-1,  
DHA-2 
DHAMF ACC TTT CAC AGG TGT GCT GGG T 405 
DHAMR CCG TAC GCA TAC TGG CTT TGC 
ACC ACCMF AAC AGC CTC AGC AGC CGG TTA 346 
ACCMR TTC GCC GCA ATC ATC CCT AGC 
MIR-1, 
 and ACT-1 
EBCMF TCG GTA AAG CCG ATG TTG CGG  302 
EBCMR CTT CCA CTG CGG CTG CCA GTT 
FOX-1 to FOX-5b FOXMF AAC ATG GGG TAT CAG GGA GAT G 190 





2.15. Phenotypic and molecular identification of CTX-M group1 genes 
For the sequencing of the CTX-M-1 group, a different set of primers was used. These 
were F 5’-CTTCCAGAATAAGGAATC-3’ and R 5’-CCGTTTCCGCTATTACAA-3’ 
with an annealing temperature of 52°C (Dutour et al, 2002). All isolates with a product 
size of 903 bp were sequenced. The sequencing was done on PCR products as described 
above. 
 
2.16. Phylogenetic determination of CTX-M-15 β-lactamase 
Escherichia coli producing isolates 
Five isolates of Escherichia coli were selected to determine their phylogenetic group. 
PCR amplification was used to determine the presence of two genes (chuA1, yjaA1) and 
a fragment of DNA known as TspE4C21. This method is to determine phylogeny as 
was proposed by Clermont et al (2000). The primers sequences and products size are 








Table 2.5: The phylogenetic genes used in this study with primers sequences and 
amplicon size.  
Name 
 


















2.17. Plasmids identification by PCR-based replicon typing 
Plasmid replicons were examined using the PCR-based replicon typing scheme 
proposed previously (Carattoli et al, 2005; Garcia-Fernandez et al, 2009). Plasmid 
replicons were examined for the ESBL-producing isolates and for transconjugants 
obtained after conjugation of some parental isolates. Replicons, primers, and amplicon 
sizes are listed in Table 2.6. 
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Primer  (5′-3′) Amplicon 
size (bp) 
References 
IncR F) TCG CTT CAT TCC TGC TTC AGC 
R) GTG TGC TGT GGT TAT GCC TCA 
251 Garcia-
Fernandez et 
al, 2009   
IncI1 F) CGAAAGCCGGACGGCAGAA 
R) TCGTCGTTCCGCCAAGTTCGT 
139 Carattoli et 
al., 2005   
IncFIA F) CCATGCTGGTTCTAGAGAAGGTG 
R) GTATATCCTTACTGGCTTCCGCAG 
462 Carattoli et 
al., 2005  
IncFIB F) GGAGTTCTGACACACGATTTTCTG 
R) CTCCCGTCGCTTCCAGGGCATT 
702 Carattoli et 
al., 2005  
IncFII F) CTGTCGTAAGCTGATGGC 
R) CTCTGCCACAAACTTCAGC 
270 Carattoli et 
al., 2005  
IncN F) GTCTAACGAGCTTACCGAAG  
R) GTTTCAACTCTGCCAAGTTC 
559 Carattoli et 




785 Carattoli et 





2.18. Pulsed-field gel electrophoresis 
PFGE was performed to determine the clonality of bacterial isolates. All of the isolates 
producing blaCTX-M genes in this study were genotyped using the PFGE protocol 
suggested by Ejrnaes et al, 2006 with some modification (see below). DNA 
fingerprinting profiles for the isolates were examined digitally with BioNumerics 
software (Applied Maths, Gent, Belgium).  
 
The isolates were grown on IST agar at 37°Cfor 24h. About 3ml of suspension buffer 
(10 mM EDTA, 1mM Tris HCL, ph8) were mixed with full loops of growth isolate 
colonies to obtain an optical density of 1.2 to 1.7 at wavelength of 600 nm. Then the 
suspension was incubated at 55°C for 10m with 500µl of TE buffer (10 mM Tris 
HCL,ph8, 100 mM EDTA). The solid agarose plugs were prepared by mixing 500µl of 
bacterial suspension with an equal volume of 1% low melting Agarose, 1%SDS, and 
25µl of proteinase K. The plugs kept in 4°C for 10 min. The plugs were kept in 5ml 
lysis buffer (50mM Tris HCL,PH 8, 50 mM EDTA, 1% laurylsarcosine) for 2h at 55°C. 
The DNA plugs were washed twice in distilled water and three times in TE buffer. For 
each wash, there was a 15 min. incubation period at 55°C. The restriction enzyme Xba1 
was then added to the plugs and incubated overnight at 37C. The DNA plugs were put 
in the well of an agarose gel and then 0.5X TBE buffer was added to cover the wells. 
The electrophoretic conditions were adjusted as follows; initial pulse time of 0.1s, 
second pulse time 38s, run time 22h, gradient v/cm. The gel was stained in GelRed and 
then photographed. The results were analysed using BioNumerics software. Strains 
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were defined as having a clonal relationship if they possessed similarity of 85% to 
PFGE profiles using 30U of Xba1 restriction enzyme on a CHEF DRII apparatus.  
 
2.19. Genome Walking and Simplex PCR for genetic environment 
studies 
PCR was used to amplify and sequence the genetic environment surrounding the blaCTX-
M-15 gene. Specific primers were used for the insertion sequences IS26 and ISEcp1 
(upstream) and for the open reading frame orf477 (downstream) in combination with 
specific primers of bla CTX-M-15 (Dhanji et al, 2011; Poirel et al , 2003; Cullik et al, 
2010, Pilhofer et al., 2007). The primers sequences and amplicon sizes used in gene 











Table 2.7: Primers sequences for GW-PCR for the detection of the upstream and 
downstream environments of blaCTX-M-15. 






























































60  (Cullik et al, 
2010:Pilhofe













AAA AAT CAC TGC GCC AGT 
 
 










2.20. Plasmid sizing and grouping 
Plasmids sizing was achieved with the prepared plugs of PFGE containing genomic 
DNA. This method used nuclease S1 (Promega), which converts the circular plasmid 
into linear structure; and permits accurate sizing by measuring the distance of the DNA 
migrated in the running gels without the interference of circular DNA. This protocol 
was suggested previously by Barton (1995). Ten units of nuclease S1 were added to 
each PFGE plug, followed by 90 μL of sterile distilled water with 10μL nuclease S1 
buffer (Promega). The PFGE plugs were incubated for 45 minutes at 37⁰C. The plugs 
washed with sterile distilled water to stop the enzymatic reaction.  
 
For isolates harbouring more than one plasmid, DNA gel extraction for each band was 
done using QIAquick gel extraction kit (Qiagen). PCR amplification was done for each 
plasmid, using primers of CTX-M primers, F 5’-CTTCCAGAATAAGGAATC-3’ and 
R 5’-CCGTTTCCGCTATTACAA-3’ at annealing temperature of 52°C (Dutour et al, 
2002) as mentioned above in section 2.15. Further sequencing was made to confirm the 
existence of blaCTX-M genes as described in part 2.4. PCR-based plasmid replicon typing 
was done as described (Carattoli et al., 2005, Garcia-Fernandez et al., 2009). The PCR 





2.21. Conjugation studies 
The transferability of the plasmids harbouring blaCTX-M genes was done by broth 
mating. The clinical isolates were used as donors and Escherichia coli J62.2 (RifR) was 
the recipient. Both had been grown in 4.5ml sterile nutrient broth after overnight 
incubation at 37⁰C. One hundred μL of the donor’s isolate cultures was added to 1 ml of 
the recipient isolate (i.e. mixed in the ratio of 1:10 donors:recipient strains) in 4.5 
prewarmed 4.5ml sterile nutrient broth and incubated overnight at 37⁰C. 
Transconjugants were cultured on MacConkey agar supplemented with rifampicin (50 
mg/L) and cefotaxime (32 mg/L) (Amyes and Gould, 1984). Controls were prepared for 
donor and recipient isolates by inoculation both of them onto MacConkey agar with the 
same antibiotics. Successful conjugation was confirmed by PCR amplification.  
 
2.22. Integron class 1 gene detection 
The primers used for amplification and detection of class 1 integron were previously 
described by Kerrn et al (2002). All blaCTX-M-producing isolates were tested for the 
presence of integron 1 gene (intI1) and then sequenced. The primers used for the PCR 
were: Int-F, 5’GCCACTGCGCCGTTACCACC3’; Int-R, 










Chapter - 3: Susceptibility Testing and Identification of 






Objectives:  The aim of this chapter was to investigate the prevalence of ESBL 
producing Enterobacteriaceae species isolated in a hospital in London. 
Results: Amongst 100 isolates received from London St George’s hospital, there were 
50 Escherichia coli, 12 Klebsiella pneuomoniae, 5 Klebsiella oxytoca, 7 Enterobacter 
cloacae, one isolate Enterobacter aerogens, one Enterobacter spp., 12 Proteus 
mirabilis, one Proteus vulgaris, six Lactose Fermenting Coliform, two isolate Pantoea 
spp., one isolate Morganella morgana, one isolate Hafnia alvei, and one isolate 
Serratia marcescens. The sensitivity of four classes of antibiotics including, third 
generation cephalosporins (cefotaxime, ceftriaxone, and ceftazidime), carbapenems 
(imipenem, meropenem, and ertapenem), fluoroquinolones (ciprofloxacin), and 
aminoglycoside (genetamicin) was examined for MIC. , Six (6%) of these isolates 
were resistant to cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, and gentamicin. 
On the other hand, all 100 isolates were sensitive to imipenem, ertapenem, and 
meropenem.  The overall frequency of ESBL producers detected in this study was 
6/100 (6%) and most of these (5/6) were from Escherichia coli and one isolate was 
from Klebsiella pneuomoniae.  
Conclusion: This work reports genotypic analysis and susceptibility profiles of clinical 







Enterobacteriaceae have emerged as one of the most significant causes of both 
nosocomial and community acquired infections. β-lactams (mainly extended-spectrum 
cephalosporins and carbapenems) and flouroquinolones antibiotics represent the main 
therapeutic options to treat infections caused by these pathogens (Canton et al, 2008). 
Extended spectrum β-lactamases (ESBLs) are class A enzymes that have the ability to 
hydrolyse third generation cephalosporins (ceftriaxone, cefotaxime, and ceftazidime) 
but are inhibited by clavulanic acid. Most of ESBLs producers are susceptible to 
cefoxitin and cefotetan but they are not active against cephamycins (Martine´z-
Martine´z et al, 1996). This study investigated the in vitro activity by the MIC of 
meropenem, ceftriaxone, cefotaxime, ceftazidime, ciprofloxacin, gentamicin, imipenem, 
ertapenem susceptibility, and clavulanate synergy with cefotaxime and ceftazidime by 





3.3. Results  
A total of 100 Enterobacteriaceae isolates were collected in 2010, from St George’s 
hospital London. From the relevant information provided by the hospital, all isolates 
were collected from blood samples. The isolates were characterised at source by Vitek 2  
Table 3.1: Total number of each Enterobacteriaceae species 
Isolate species Number of 
isolates 
E.coli 50 
Klebsiella spp 17 
Enterobacter spp 9 
Proteus sp 13 
Lactose fermenting coliform 6 
Pantoea sp 2 
Serratia marcescens 1 
Morganella morganii 1 




















Antimicrobial agent mg/L 
MIC50 MIC90 MIC 
Range 
E. coli  
 50 
 
Cefotaxime  0.06 0.25 0.03-128 
Ceftriaxone 0.06 0.25 0.015-128 
Ceftazidime  0.12 0.25 0.03-164 
Ciprofloxacin  8 32 0.5-64 
Gentamicin  1 32 0.25-128 
Imipenem  0.03 0.12 0.008-0.5 
Meropenem  0.03 0.5 0.008-0.5 




Cefotaxime 0.03 0.06 0.03-128 
Ceftriaxone 0.06 0.25 0.015-128 
Ceftazidime 0.12 0.25 0.06-128 
Ciprofloxacin 1 8 0.5-16 
Gentamicin 1 8 0.5-32 
Imipenem 0.015 0.06 0.008-0.25 
Meropenem 0.03 0.06 0.008-0.12 
Ertapenem 0.06 0.5 0.03-0.5 
Proteus spp  
13 
Cefotaxime 0.03 0.12 0.03-0.12 
Ceftriaxone 0.06 0.12 0.015-0.12 
Ceftazidime 0.12 0.5 0.12-0.5 
Ciprofloxacin 2 32 0.5-32 
Gentamicin 0.5 1 0.5-1 
Imipenem 0.015 0.06 0.008-0.12 
Meropenem 0.03 0.06 0.008-0.06 
Ertapenem 0.06 0.5 0.03-0.12 
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3.3.1 Antimicrobial susceptibility 
All of the collected isolates were initially examined to determine the MIC of 
meropenem to exclude the presence of carbapenemases. None of the 100 isolates had an 
MIC above the breakpoint thus showing complete susceptibility to meropenem and the 
presence of carbapenemase activity was not examined further. 
 
The MICs of the antibiotics used and other results for these isolates are shown in the 
Appendix. The MIC range, MIC50 and MIC90 values for the individual for all 100 
isolates are shown in Table 3.2.  
 
Six isolates (five Escherichia coli and one Klebsiella pneumoniae) were shown to be 
resistant to the cephalosporins. The MICs showed that all of these isolates were 






Table 3.3: MICs of ESBL producing Escherichia coli and Klebsiella pneumoniae 
isolates (MIC: mg/L), and synergy of both cefotaxime and ceftazidime with clavulanate. 
Grey colour indicates resistant isolates. 
Isolate N
o. 





























9 8 32 64 8 0.015 0.015 0.5 8 + + 
10 8 32 32 8 0.12 0.015 0.5 8 + + 
12 16 >128 64 16 0.008 0.06 0.5 8 + + 
23 16 >128 64 8 0.12 0.12 0.03 16 + + 
25 16 >128 >128 64 0.06 0.008 0.03 8 + + 




3.3.2. Confirmation of ESBLs production 
All isolates that had been found to be resistance to cefotaxime, ceftazidime, and 
ceftriaxone were subjected to confirmatory tests by the double and combination disc 
diffusion methods as described previously in the Materials and Methods (2.12) and 
shown in Figures 3.1. All were found to show positive synergy with cefotaxime plus 





Figure 3.1. Example of synergy by the double disc detection method for ESBL 
production. Discs: centre, amoxicillin + clavulanate 20 + 10μg; up, cefotaxime 30μg; 




3.3.3. CTX-M genes detection by Multiplex PCR  
Multiplex PCR was performed for the identification of blaCTX-M genes using specific 
primers designed for identifying known β-lactamase genes including individual 
blaCTX-M groups 1, 2, 9, and jointly blaCTX-M groups 8 and 25. All six isolates had the 
intrinsic alleles of blaCTX-M group 1. The gene encoding CTX-M group 1 
β-lactamases is located on an amplicon of 415bp while characteristic amplicons of 




                           
                                
      
      
                        
                                     
 
 
Figure 3.2: Multiplex PCR for CTX-M shows six positive isolates for CTX-M group 1. C1; 
positive control for CTX-M group1 (415pb); N, negative control; 9, 10, 12, 23, and 25, E 



















Figure 3.3: Multiplex PCR for CTX-M genes shows examples of five 
cephalosporin sensitive isolates contain nonspecific sequences along with three 
CTX-M control genes(C1 = group 1, C2 = group 9 and C3 = group 2), these 
genes have expected band size of 415 pb for group 1, 552 pb for group 2, and 
205 pb for group 9. 9, 10, 12, 23, and 25, E coli; 60, K. pneumoniae; M=marker 
(1kb), N=negative control. 
 
 
3.3.4. blaAmpC genes Multiplex PCR 
Multiplex PCR was performed to detect AmpC β-lactamase genes (Perez & Hanson, 
2002). using specific primers for PCR amplifications. These primers are listed in 
table 2.4 in the Material and Methods. blaAmpC genes were not found in any isolates 












Figure 3.4:  Analysis of blaAmpC genes in the six cephalosporin resistant clinical 
isolates. Multiplex PCR products were separated in a 1.5 agarose gel. M, 1 kb DNA 
ladder; N, negative control (distilled water); C1, positive control with two genes, CIT 
(462 bp) and EBC (302 bp) family genes; C2, positive control with one gene, FOX 
(190 pb) family gene; all other isolate shows negative isolates. 
 
  









The extended-spectrum β-lactamases (ESBLs) are one of the most alarming groups 
of β-lactamases in clinical practice. There are many reports of increased mortality 
and deteriorating clinical outcomes for infections caused by bacteria encoding 
ESBLs (Paterson et al, 2004). Bacteria harbouring ESBLs have been isolated from 
infections, such as septicemia, urinary tract infection, hospital acquired pneumonia, 
brain abscesses, intra-abdominal abscesses (Mathur, 2002). ESBLs can be defined as 
β-lactamases capable of donating bacterial resistance to penicillins, first-, second-, 
and third-generation cephalosporins and monobactams (e.g.aztreonam), but not the 
cephamycins or carbapenems but can be inhibited by β-lactamase inhibitors such as 
clavulanic acid. According to the latter definition, functional classification places 
most ESBLs into group 2Be.  
The majority of ESBLs contains a serine at the active site, and belongs to class A 
according to the Ambler classification (Ambler, 1980). Today, there are >180 TEM 
type, >130 SHV type, >90 CTX-M type, and 11 OXA type β-lactamases 
(http://www.lahey.org/studies/). ESBLs produced by Enterobacteriaceae, particularly 
those of the CTX-M type, are a major problem globally (Paterson and Bonomo, 
2005). CTX-M variants have now subrogated TEM and SHV enzymes as the most 
common ESBLs produced by gram negative bacteria, particularly Klebsiella 
pneumoniae and E. coli (Livermore et al, 2007). CTX-M predominantly cleaves 
cefotaxime more than ceftazidime, although some variability has been reported (Bou, 




Different ESBLs exhibit different levels of resistance to third generation 
cephalosporins (Gupta, 2007). Many do not increase MICs to levels that can be 
described as resistance while some reduce MICs below the standard breakpoints 
(sometimes as low at 0.5mg/L) for resistance (Katsanis et al, 1994). Clinical failure 
can be associated with even weak ESBL activities. It is therefore essential to test 
ESBL detection to identify the start of the ESBL evolution (Gupta, 2007). It is risky 
to rely on a single screening antibiotic, such as ceftazidime or cefpodoxime, in a 
screening test (Sturenburgh & Mack, 2003). There have been many failures in both 
disc diffusion and MIC tests alone to detect ESBLs (Jacoby and Han, 1996). Also, 
there are reports showing the failure of automated tests for ESBLs detection 
(Tenover et al, 1999). The utilization of more than one cephalosporing group will 
increase ESBL detection sensitivity (Federico et al, 2007). In addition, the reporting 
of ESBL- producers should state that these isolates are considered resistant to all 
penicillins, cephalosporins, and aztreonam (CLSI, 2007). More importantly, 
molecular detection tests are much more sensitive for specific ESBL detection 
though they may not measure expression. These methods include: specific DNA 
probes, PCR with oligonucloetide primers oligotyping, ligase chain reaction and 
sequencing of nucleotide, and PCR followed by restriction fragment polymorphism 
analysis (Gupta, 2007). In this study, MIC’s for three third generation cephalosporins 
were used and then synrgy dis confirmatory test was used to confirm the presence of 





A third generation cephalosporins resistant E. coli and Klebsiella pneumoniae are 
however, not ESBL producers. Some plasmid-encoding AmpC β-lactamases may be 
acquired by Klebsiella spp (Bush, 2008) and E. coli (Paterson, 2001). The ESBL 
confirmatory tests such cases do not give positive results for AmpC enzymes 
carrying isolates.  
 
 
The prevalence of ESBL producing species of the family of Enterobacteriaceae 
varies in different parts of the world. The prevalence of ESBL-producing bacteria has 
been reported from North America, South America, Africa, Asia, and Europe 
(Dhillon and Clark, 2012). Data collected from different parts of the world showed 
the rate of ESBL production was highest among the Klebsiella pneumoniae strains 
from South America, Asia/Pacific Rim, Europe, and North America (44%, 22.4%, 
13.3%, and 7.5%, respectively) (Reinert et al, 2007; Falagas & Karageorgopoulos, 
209). In China, data in 1998-1999 suggested that ESBL-producing E. coli and K. 
pneumoniae isolates, ranged from 13% - 15% and >20% respectively. Recent study 
observed a significant increasing in the ESBLs-producing Escherichis coli over the 
non- ESBLs-producing Escherichis coli in rates of 47.9% and 52.1% respectively (Li 
et al, 2012). The situation in Africa is unrelaible due to a lack of comprehensive data, 
though there is sufficient evidence suggested the prevalence of ESBLs- producing 




In Europe, although there is prevalence of ESBLs in  different European countries, 
the ESBL-producing Enterobacteriaceae is alarming. several European countries 
have experienced outbreaks associated with ESBL-producing bacteria (Paterson and 
Bonomo, 2005). There has been a slight decrease in the number of ESBL- producing 
K. pneumoniae in Western Europe, probably because of improvements in infection 
control and antimicrobial management (Albertini et al, 2002). Data reported in 2006 
from 31 European countries showed a continuous rise in resistance to third 
generation cephalosporins since 2000 both in E.coli and Klebsiella pneumoniae 
isolates (EARSS, 2006). The latter data showed significant geographical differences 
from 1% in Estonia to 41% in Romania for E.  coli and 0% in Iceland to 91% in 
Romania for Klebsiella pneumoniae. A study from Denmark showed the prevalence 
of ESBL producers was less that 1% (Kjerulf  et al, 2008). In France, the frequency 
of different ESBL producing isolates in 2005 was lower that described in previous 
years such as Klebsiella pneumoniae (9.4% versus 3.71%), but had rised for E. coli 
(0.2% versus 2%) (Galas et al, 2008).  
 
These data compare with those from isolates in Asia/Pacific Rim, Europe, and Latin 
and North America, which showed that the proportion of ESBL production in E. coli 
and K. pneumoniae was 7.6% and 7.5% respectively during a similar period. Other 
study from 22 European countries showed the proportion of ESBL production among 
794 Escherichia coli isolates and 515 Klebsiella pneumoniae isolates was 9.8% and 
15.5%, respectively (Hack et al, 2008). Data collected from tertiary hospitals, similar 
to St George’s, and intensive care units in the United Kingdom reported that the rate 
of Enterobacteriaceae producing ESBLs increased from 4.8% in 1997 to 7.4% in 
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2002 (Masterton & Turner, 2006). Additionally, data received from BSAC reported 
an elevation in bacteraemia cases due to CTX-M producing Escherichia coli from 
0.9% in 2002 to 8.3% in 2007 and for K. pneumoniae from 0.9% to 11.8% over the 
same time period (www.bsacsurv.org/mrsweb/bacteraemia). This is reflected in my 
results, where 10% of the E. coli strains were cephalosporin resistant and ESBL 
positive. Although 6% of the Klebsiella isolates were cephalosporin resistant and 
ESBL positive, the percentage cannot be accurate because of the number of strains. 
 
My results also show the association of other resistance determinants with 
cephalosporin resistance. The following chapters will examine whether these 
resistance genes are linked to the β-lactamase gene. Multi-resistance provides the 
bacteria with an obvious selective advantage, but it is also advantageous to the 
survival of β-lactamase gene as its will be maintained by the use of antibiotics other 
than the cephalosporins. A report has shown that the use of various antibiotics has 
been associated with the emergence and persistence of the ESBL-producing 
Enterobacteriaceae. It demonstrated that the use of quinolones was a risk factor in the 




These findings report the distribution of ESBLs among the clinical isolates obtained 
from St George’s Hospital London. The cephalosporin resistance and extended-
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spectrum β-lactamases detected in this work represented a lower rate of resistance 
than other recent findings worldwide. On the other hand, this study confirms the 






Chapter - 4: Prevalence of transferable blaCTX-M-15 from 
hospital-acquired Escherichia coli and Klebsiella 








Objectives: This chapter investigated the prevalence and molecular characteristics of 
transferable blaCTX-M-15 from hospital-acquired Escherichia coli and Klebsiella 
pneumoniae isolates in London.  
Methods: A total of 100 clinical isolates of various isolates of Enterobacteriaceae 
received from London St George’s hospital in 2010. The isolates showed six of them 
harbouring CTX-M type ESBLs producers. Conujugation was done to determine 
where the blaCTX-M-15 gene was transferable. The isolates and transconjugants were 
examined for antimicrobial susceptibility by MICs and agar double dilution method. 
PCR and sequencing were used to detect blaCTX-M-15 gene. Phylogenetic analysis was 
done by multiplex PCR for the five isolates of Escherichia coli. 
Results: Six (6%) isolates had been found to harbour the blaCTX-M-15, five 
Escherichia coli (and three transconjugants) and one Klebsiella pneumoniae isolate. 
In addition, sequencing confirmed the existence of blaCTX-M-15 and the conjugation 
showed the ability of blaCTX-M-15 to transfer. Phylogenetic analysis showed A and B2 
groups of Escherichia coli isolates.  
Conclusion: This chapter identified the mobile element responsible for the 






4.2. Introduction  
Enterobacteriaceae harbouring extended-spectrum β-lactamases (ESBLs), 
specifically those of the CTX-M type, are a problem worldwide, causing both 
sporadic infections and outbreaks (Paterson & Bonomo, 2005). Some recent studies 
suggested that the pandemic dissemination of the CTX-M-15 β-lactamase is due to 
the highly virulent Escherichia coli O25:H4-ST131 (Leflon-Guibout et al, 2008; 
Woodford, 2008). 
 
The CTX-M-15 β-lactamase was described in the United Kingdom in 2001 (Mushtaq 
et al, 2003), and was first reported in 1999 in India (Karim et al, 2001). The bacterial 
strains producing enzyme spread rapidly in the United Kingdom since its first 
emergence in 2001. During that dissemination, the United Kingdom isolates were 
often associated with different E. coli clones that had previously been detected 
worldwide (Laupland et al, 2008).  
 
The blaCTX-M-15 gene is also associated with other resistance genes and is mostly 
located on plasmids, and normally belong to the IncF group (Bonnet, 2004). These 
plasmids contain more than one replicon and in multireplicon plasmids, one replicon 
is necessarily conserved, owing of the selective pressure causing duplication of the 
plasmid, while the other replicon is free to diverge (Sykora, 1992). The IncF 
plasmids are not, therefore, an homogeneous group of plasmids as they vary in size 
between 50 to 200kb and have the ability to carry the repFII replicon alone or in 




Interestingly, in the United Kingdom, the IncF plasmids harbouring the blaCTX-M-15 
gene are not associated with specific clones, such as Escherichia coli ST131, but 
rather they have other Escherichia coli sequence type, including ST405, ST354, 
ST28, and ST695 as well as in other species of the Enterobacteriaceae (Coque et al, 
2008; Diestra et al, 2009; Hrabak et al, 2008). Variants of the CTX-M β-lactamase 
are often confined within localised geographical areas, such as the CTX-M-3 
β-lactamase in Eastern European countries, and the CTX-M-9 and CTX-M-14 
β-lactamase in both Spain and Portugal (Coque et al, 2008; Navarro et al; 2007, 
Novais et al, 2007). It should be noted that the latter two are closely related to one 
another. It is has not been identified why this localised distribution occurs but it is 




4.3.1 Conjugation results 
 
By using conjugation method listed in the Section 2.21 in Materials and Methods 
section, transconjugant plasmids were successfully transferred from isolates 9, 10, 
and 25 of E. coli strains. Transconjugants could not be obtained fom the other three 






4.3.2. PCR amplification and sequencing of CTX-M-15 genes. 
The overall frequency of ESBLs-producing Escherichia coli and Klebsiella spp 
detected in this study had been 5/50 (10%) and 1/17 (6%) respectively. The 
multiplex PCR had shown the existence of blaCTX-M-1 group genes (Chapter 3) in 
these six isolates. These six isolates and the three transconjugants were further tested 
by PCR with specific primers for the blaCTX-M-1 group. These primers, CTX-M-1A 
and CTX-M-1B, are listed in 2.15 in Material and Methods section (Dutour, Bonnet 
et al, 2002). Each isolate yielded a 903bp product for CTX-M-15 gene (Figure 4.1). 
The results observed that CTX-M-1 genes were seen in the six isolates of E. coli and 
Klebsiella pneumoniae and three transconjugants of from isolates 9, 10 and 25  
 
All isolates showed the presence of the gene. The PCR products were then sent for 
sequencing. The nucleotide sequence data was analysed and identical for each of the 
six isolates and identical to previous submissions to GENBANK for blaCTX-M-15. The 
deduced amino acid sequence was identical with the CTX-M-15 β-lactamase in each 
of the six strains (Figure 4.2). The common sequence from this study was deposited 









Figure 4.1: PCR amplification of CTX-M-15 β-lactamase genes (903 bp band) for 
the isolates and transconjugants. The isolate numbers are shown at the top of each 
lane. The respective isolates are E. coli 9, 10, 12, 23, and 25, E coli and K. pneumoniae 
strain 60, Those that have the suffix T are transconjugants from these isolates. Lane 









Figure 4.2: Nucleotide differences between isolates sharing 98-99% similarity with 
blaCTX-M-15 sequences. Areas in red are identical, black indicates low consensus, and 
blue indicates neutral consensus. 
 
4.3.3. The β-lactam susceptibility profile 
The pattern of resistance to antimicrobial agents in all 6 cefotaxime-resistance E. coli 
and K. pneumoniae isolates and their corresponding transconugants (9, 10, and 25) is 
shown in Table 4.1. The antimicrobial susceptibility patterns revealed that all the 
isolates that harboured CTX-M-15 ESBLs were characterized by high resistance to 
all cephalosporins examined. The resistance was transferred with the β-lactamase 
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gene. Although the co-transfer of gentamicin resistance seen might be expected, the 
co-transfer of ciprofloxacin resistance was not, indicating the presence of plasmid-
mediated quinolone resistance genes. The transconjugants were susceptible to 
carbapenems as expected (Table 4.1). 
Table 4.1: MICs antimicrobial susceptibility test of ESBL producing Escherichia coli 
and Klebsiella pneumoniae isolates and their corresponding transconjugants (MIC: 

























9 8 32 64 8 0.015 0.015 0.5 8 
10 8 32 32 8 0.12 0.015 0.5 8 
12 16 >128 64 16 0.008 0.06 0.5 8 
23 16 >128 64 8 0.12 0.12 0.03 16 
25 16 >128 >128 64 0.06 0.008 0.03 8 
60 16 >128 >128 >128 0.06 0.03 0.06 16 
T9 8 32 64 8 0.015 0.015 0.5 8 
T10 8 32 32 8 0.12 0.015 0.5 8 
T25 16 128 128 64 0.06 0.008 0.03 8 
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4.3.4. Phylogenetic analysis of Escherichia coli isolates 
Phylogenetic studies have proposed that Escherichia coli may be classified into four 
main groups or clusters; the more virulent cluster B2 and the low extent cluster D, 
and cluster A or B1 the commensal strains (Clermont, Bonacors & Bingen, 2000). 
Although, virulence factors are known to be mobile, a connection between virulence 
and strain phylogeny has been described (Picard et al, 1999). The B2 phylogenetic 
group represents the majority of strains involved in extraintestinal infections and is 
deeply divergent from other strains. Such virulence determinants within certain 
phylogenetic group in a species represent a clonal regardless horizontal gene transfer 
(Desjardins et al, 1995) permits the evolution of an early genetic divergence within 
the E. coli species which may led to descriminate phylogenetic group A and B1 
commensal strains, on the one hand, and to phylogentic group B2 of pathogenic 
strains, on the other hand. The former group of strains emerged as extraintestinal 
virulence by obtainig of numerous pathogenic determimnants (Lecointre et al, 1998). 
However, there is a stable connection between virulence and phylogeny as virulenc 
determinants organise into the right genetic background, resulting into certain clone 
which represents the microbial pathogeneicity in pathogeneic bacteria (Neidhardt et 
al, 1996).  
The method of phylogenetic classification of extra-intestinal pathogenic Escherichia 
coli depends on the identification and combination of two preserved genes (chuA and 
yjaA) and the DNA fragment TSP (Clermont et al, 2000). Therefore each strain was 
examined by a multiplex PCR for the carriage of the two preserved gene and the 
DNA fragment TSP. The PCR was run as described in the Materials and Methods 
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and the amplicons were separated on a gel (Figure 4.3). The results of these three 
amplifications are tabulated in Table 4.2 and this allowed the creation of a 
dichotomous decision tree (Figure 4.4) for phylogenetic grouping. From this 
information, two E. coli isolates (9 and 10) were identified as phylogenetic group A 
and the rest of E. coli isolates (12, 23 and 25) were showed group B2.  
   
Figure 4.3: Triplex PCR amplification of chuA (279bp), yjaA (211bp), and fragment 
TspE4C2 (152bp) for identification of the phylogenetic groups of Escherichia coli 
isolates 9, 10, 12, 23, and 25. Lanes M: 100 Kb marker. Lane N: negative control 
(free DNA).  The isolate numbers are listed at the top of each lane. 
 
 











































Table 4.2: Identification of the preserved genes in E. coli to determine phyogenetic 
class. 
E. coli isolate chuA yjaA TspE4C2 
9 - + - 
10 - + - 
12 + + - 
23 + + - 

























Figure 4.4: Dichotomous decision tree to detect the phylogenetic group of an E. coli 
strain by using the PCR amplification results of the chuA and yjaA genes and DNA 





B1 or A B2 or D 
TspE4.C2 yjaA 




In this study, the CTX-M-15 β-lactamase was the only ESBL found in the six 
cephalosporin resistant strains in E. coli and Klebsiella pneumoniae. CTX-M-15 β-
lactamase has also been detected in hospitals and community as well as in 
companion animals in the United States and other parts of the world, (Castanheira et 
al, 2008; Urban et al, 2010; Shaheen et al, 2011), it is the presence of the CTX-M-15 
β-lactamase in European countries that may bear most relevance to this study. A 
study from Russia identified the blaCTX-M gene in 35.9% of Escherichia coli and 
34.9% of Klebsiella pneumoniae ESBL producing isolates (Edelstein et al, 2003). In 
Austria, among 149 ESBL-producing Enterobacteriaceae isolates obtained between 
1998 and 2004, 49 were CTX-M family producers, 38 in Escherichia coli and 11 in 
Klebsiella spp. The majority of these CTX-M-producers carried the CTX-M-15 β-
lactamase, while the rest harboured CTX-M group 9 β-lactamases (Eisner et al, 
2006). A study in Poland showed that the prevalence of the CTX-M-15 β-lactamase 
was high in Serratia marcescens and Escherichia coli in collection of ESBLs 
Enterobacteriaceae producers (Baraniak et al, 2002). All the studies show that the 
CTX-M-15 β-lactamase quickly comprised not only a high proportion of the ESBL 
producing strains but was also highly prevalent in the individual populations as a 
whole. It is therefore suprising that the proportion of cephalosporin resistance and the 
concomitant number of CTX-M-15 β-lactamase producers was much lower in St 
George’s Hospital, not least for the fact that the isolation of these bacteria was many 




The pattern of antimicrobial resistance in in the CTX-M-15 6 β-lactamase containing 
isolates showed there was cross-resistance to ceftriaxone (6), cefotaxime (6), 
ceftazidime (6), ciprofloxacin (6), gentamicin (6), meropenem (0), imipenem (0) and 
ertapenem (0), the proportion that was cross-resistace is shown in parentheses. This 
high proportion of resistance to majority of the antibiotics is facilitated by the fact 
that the blaCTX-M genes are frequently present on plasmids harbouring genes that give 
resistance to multiple antibiotics, including chloramphenicol, aminoglycosides, 
trimethoprim, sulphonamide, and tetracycline (Bonnet, 2004).  
 
The CTX-M β-lactamases confer high levels of resistance to cefotaxime, ceftriaxone, 
and aztreonam but often less so to ceftazidime (Bonnet et al, 2002; Saladin et al, 
2002). CTX-M-15 β-lactamase is an exception and is the member of this group that 
gives the highest resistance to this cephalosporin. This is due to the origin of the 
CTX-M-15 β-lactamase; it originated from the CTX-M-3 β-lactamase, which does 
not confer ceftazidime resistance (Poirel et al, 2002). The substitution of glycine for 
asparate at position 240, on the β-3 sheet to the right hand side of the active site 
improves the catalytic activity against ceftazidime by increasing the rate of binding 
and hydrolysis of this cephalosporin (DuBois et al, 1995). The prevalence of the 
CTX-M-15 β-lactamase in the UK and in Eastern Europe therefore suggests the use 
of ceftazidime over other cephalosporins.  
 
ESBL producing isolates are often resistant to different families of antibiotics beside 
β-lactams including, fluoroquinolones (ciprofloxacin), diaminopyrimidimes plus 
118 
 
sulfonamides (co-trimoxazole) and aminoglycosides (gentamicin, amikacin), which 
suggest that many other factors could promote the persistence of multi-drug resistant 
ESBL producer strains and plasmids in both community and clinical settings (Canton 
et al, 2008). High rates of resistance against ciprofloxacin in CTX-M β-lactamase 
producing clinical isolates have been described in previous studies outside the United 
Kingdom (Pitout et al, 2005; Eisner et al, 2006). The blaCTX-M-15 gene has been found 
to be linked to genes conferring resistance to co-trimoxazole, gentamicin, and 
ciprofloxacin in E. coli isolates in Canada (Pitout et al, 2007). In my study, the 
transconjugants were also resistant to ciprofloxacin; a fluoroquinolone resistance 
gene linked to the blaCTX-M-15 gene is unusual in isolates from the United Kingdom. 
 
The majority of the blaCTX-M-1 group clusters and the blaCTX-M-9 clusters belong to 
phylogenetic groups B2 and D, respectively (Pitout et al, 2005; Karisik et al, 2008; 
Lee et al, 2010) so it was unusual to find two strains in group A. In addition, the 
pathogenic strains causing bacteraemia or urinary tract infection mainly belonged to 
groups B2 and D (Russo and Johnson, 2000; Duriez et al, 2001; Lee et al, 2010), 
which correlates well with this study as the isolates were all obtained from blood 
samples and the majority of these strains belonged to phylogenetic group B2. 
Another study suggested that CTX-M-producing Escherichia coli were more 
associated to the rare D2 genotype (Branger et al, 2005). However, it was reported 
that the B2 epidemic strains are the predominant strains disseminating the CTX-M-
15 β-lactamase in the United Kingdom (Karisik et al, 2008). My isolates were 
obtained from a population living in an area of London (Tooting) with diverse 
origins, in particular there is mass movement between Tooting and India and 
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Pakistan. One study from India suggested that phylogenetic groups D and B2 are 
predominant (Guiral et al, 2011), whereas a later study by the same group from India 
identified that phylogenetic group B2 was the commonest, while group A was the 
second (Guiral et al, 2013). In Pakistan, it has been found that phylogenetic group A 
was the most frequent followed by phylogenetic group B2 (Saeed et al, 2009). This 
later study could explain my results for samples 9 and 10 which were identified as 
phylogenetic group A. 
4.5. Conclusion 
This study has demonstrated that the gene of blaCTX-M-15 can be transferred by 
conjugation and the plasmid harboured resistance determinants to gentamicin and 
ciprofloxacin. In addition, phylogenetic analysis showed that my isolates belong to 








Chapter – 5: Variations in genetic environments in 
conjugative IncFI plasmids carrying CTX-M-15 among 
Escherichia coli and Klebsiella pneumoniae ESBL producing 







Objectives: To identify the molecular epidemiology of CTX-M-15 type ESBL 
producing Escherichia coli (5) and Klebsiella pneumoniae (1) isolates at St George’s 
hospital London. 
Results: Examination of the six harbouring blaCTX-M-15 alleles revealed two 
phylogenetic groups A and B2. The analysis of PFGE-based patterns showed that 
only two Escherichia coli isolates have more than 85% clonal similarity, while the 
rest were less similar. The transferable cefotaxime resistance was manifested by 
plasmids size ranging from 78.0 kb and 152.0 kb. In these isolates, conjugative 
IncFIA and IncFIB plasmids were detected in 5/6 and 4/6 of the ESBL-type CTX-M 
producers respectively. Analysis of the genetic environments showed that there were 
five different genetic arrangements surrounding the blaCTX-M-15 gene including 
various truncations of ISEcp1. 
Conclusion: The blaCTX-M-15 gene was found in five different genetic arrangements 
through various length of truncated ISEcp1. The presence of ISEcp1 indicates 
acquisition of the gene perhaps from outside the United Kingdom but the variation 
suggests in the genetic environment and the strain genotype indicates that direct 





Bacterial plasmids carry non-essential accessory genetic structures and have varying 
size from few to hundreds of kilobases. In order to be auto-transferable, a plasmid 
needs to be greater than about 30kb and they have to be greater than 20kb to carry 
insertion sequences. Auto-transferable plasmids, passing through different strains, 
pick up transposons largely through the action of insertion sequences and this has 
been the main mechanism for the acquisition of antibiotic resistance genes. There is 
an abundance of insertion sequences in auto-transferable plasmids. The recognition 
and localization of both full length insertion sequences and fragmented sections 
identifies how the modular assemblies of genes are formed (Hu & Derbyshire, 1998). 
 
Genes harbouring ESBLs are linked to certaingenetic elements. Specific mobile 
genetic structures, insertion sequences, transposons, and integrons, have had 
important roles in the spread of ESBL genes (Poirel, Naas & Nordmann, 2008). 
However, compared with the spread of TEM and SHV ESBL genes, the 
dissemination of CTX-M-type ESBL genes are linked to more complicated mobile 
structures (Canton & Coque, 2006). This may be because the TEM and SHV ESBL 
genes were mainly derived from Escherichia coli (Livermore, 1995) and Klebsiella 
pneuomoniae (Babini & Livermore, 2000) respectively and therefore did not have 
species barriers to overcome; while the CTX-M genes had to migrate from Kluyvera 
species and this will inevitably required more sophistaicated genetic manipulations in 




5.3. Genotyping by Pulsed-Field Gel Electrophoresis (PFGE) 
Pulsed-Field Gel Electrophoresis (PFGE) (Schwartz et al, 1982) separates 
chromosomal DNA fragments larger than 50kb, created by endonuclease digestion, 
with two alternating electronic fields. It is thus a useful technique to determine the 
degree of relatedness between different strains of the same species (Correia, Martin, 
and Castro, 1994) and is considered to be the “gold standard” for strain typing and 
bacterial phylogeny. It can also provide information on the degree and frequency of 
horizontal gene transmission and gene conversion, molecular organization of 
chromosome, and genomic re-arrangements (Lahti, 1996).  
 
In this study, PFGE typing was used to analyse the six cephalosporin-resistant 
isolates (5 E. coli and one Klebsiella pneumoniae) obtained from St George’s 
hospital London. Figure 5.1 shows the PFGE profile of the six strains and it revealed 
that only two strains were similar (96%) while the others showed less than 85% 
similarity to these two isolates and to each other. The dendrogram analysis shows six 






Figure 5.1: PFGE patterns of 5 E. coli and one Klebsiella pneumoniae clusters 9, 10, 
12, 23, 25, and 60. Lanes M: Lambda ladder PFG markers standard size. The isolate 
numbers are shown at the top of each lane. The respective isolates are E. coli 9, 10, 
12, 23, and 25, E coli and K. pneumoniae strain 60,  
 
 





Figure 5.2: Dendrogram analysis of six isolates. Dendrogram showing the 
relationship between isolates of five strains of Escherichia coli and one strain of 
Klebsiella pneumoniae obtained after Xba1 digestion of the chromosomal DNA. 
 
5.4. Plasmid identification by PCR-based replicon typing for CTX-
M-15 plasmids  
The ability to describe plasmids accurately is an essential part of epidemiologic 
studyand healthcare management, particularly during the  epidemic plasmids spread 
in the population. This helps to take appropriate infection control measures (Coque, 
Baquero & Canton, 2008). The ability to classify and recognise plasmids in 
homogenous groups according to phylogenetic similarities is essential to determine 
their dissemination in nature and their evolutionary origin (Francia, et al, 2004) and 
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also to track the dissemination of plasmids donating antimicrobial resistance 
(Anderson et al, 1977). The scheme of a plasmid classification based on the plasmids 
stability during conjugation, process named plasmid incompatibility (Inc) (Datta and 
Hedges, 1971). Plasmids with related replication control system are known to be 
incompatible with each other in the same cell (Datta and Hedges, 1971). Carattoli et 
al (2005) instigated a PCR based replicon typing for the identification of Inc groups 
and recognised 27 different Inc groups in Enterobacteriaceae (Carattoli 2009) 
Several studies have reported that many plasmids in the Enterobacteriaceae either 
have replicons of the IncFII group, or multi-replicons of IncFII linked with IncFIA 
and/or IncFIB (Gonullu et al, 2008). 
In this study, PCR amplification was done using primers listed in Table 2.6 in the 
Materials and Methods to detect replicons of five plasmid incompatibility groups 
(IncI1, IncFIA, IncFIB, IncFII, and IncR) according to Carattoli et al (2005). The 
results showed the presence of replicon IncFIA in all isolates, except isolate 60, and 
in each of the transconjugants (Figure 5.3). Replicon IncFIB was found in isolates 9, 
10, 12 and 23 and in the transconjugants from isolates 9 and 10. Replicon IncFIB 
was not found in isolates 25 and 60, nor of course in the transconjugant of isolate 25 
(Figure 5.4). Isolate 60 was a Klebsiella pneumoniae strain, from which it is often 
difficult to identify Inc groups by the ordinary PCR based replicon typing. Therefore 
when S1 nuclease was used to isolate plasmids from this strain, the Inc typing was 




Figure 5.3: PCR amplification of IncFIA replicon (462 pb). Lanes M: 1 Kb marker. 
Lane N: negative control (free DNA). The isolate numbers are shown at the top of 
each lane. The respective isolates are E. coli 9, 10, 12, 23, and 25, E coli and 




Figure 5.4: PCR amplification of IncFIB replicon (702 pb). Lanes M: 1 Kb-pb 
markers. Lane N: negative control (free DNA). The isolate numbers are shown at the 










M       N        9       10      12      23       25      60      9T     10T     25T     M 
M      N          9       10       12       23      25      60      9T     10T   25T 
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5.5. Determination of plasmid profiles by Nuclease S1 digestion 
Plasmids greater than 100kb in size are called megaplasmids, representing about 10-
20% of the  genetic material of the bacterium. Large plasmids make a significant 
contribution to the genomic polymorphism of bacteria, genetic horizontal transfer, 
and plasmid evolution, so a technique for identifying and sizing the plasmid  DNA is 
often crucial. These megaplasmids are too large to determine in conventional gel 
electrophoresis, as there are naturally covalently closed-circular supercoiled 
molecules and their migration is unpredictable in PFGEunlike  Linear DNA, which 
migrates more predictably in a PFGR gel and thus could be used for accurate size 
determination. When S1 nuclease is added, it nicks the supercoiled plasmids to 
release linearized DNA (Germond, Vogt & Hirt, 1974). When linear plasmid DNA is 
separated by PFGE, it can provide an accurate measurement of size when compared 
against suitable markers (Barton et al, 1995). 
 
In this study, each plasmid from both from the isolates and the transconjugants, 
which had undergone PCR-replicon typing, was extracted from the gel and digested 
with S1 nuclease and run on a PFGE gel. Furthermore, plasmid number and sizing 
was also done on the five Escherichia coli isolates and one Klebsiella pneumonia 
isolate as well as all associated transconjugants with the total DNA treated with S1 
nuclease. 
 
The plasmid sizes are shown in Figure 5.5. All bacteria strains had one detectable 
plasmid except one Escherichia coli strain and Klebsiella pneumoniae strain, both of 
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which possessed three plasmids of different sizes. The co-existence of Inc FIA and 
FIB replicons were found in all plasmids isolates except one plasmid belonging to 
Escherichia coli, Klebsiella pneumoniae and one of the transconjugants. Inc FIA 
replicon was found alone in one plasmid of Escherichia coli a transconjugant. Inc 
FIB replicon was found alone only in one transconjugant. Two plasmids of 
Escherichia coli and one of Klebsiella pneumoniae did not have incompatibility 







Figure 5.5: Agarose gel showing S1 nuclease PGFE based sizing of large plasmids 
for 9 isolates. M (Size Marker) refers to the molecular weight marker of the 
bacteriophage lambda genome. The isolate numbers are shown at the top of each 
lane. The respective isolates are E. coli 9, 10, 12, 23, and 25, E coli and K. pneumoniae 
strain 60, Those that have the suffix T are transconjugants from these isolates. 
Plasmids shows variable sizes ranging from 152.0kb to 78.0kb of isolates 9, 10, 12, 




Table 5.1: Plasmid sizes and incompatibility grouping of the 6 blaCTX-M-15 containing 
strains and the transconjugants. 









9 E. coli  Plasmid 147 + F1A, FIB 
10 E. coli  Plasmid 147 + F1A, FIB 
12 E. coli  Plasmid 152 + F1A, FIB 
23 E. coli  Plasmid 152 + F1A, FIB 
25 E. coli  
 
3 Plasmids 129 +  F1A 
96 - - 




3 Plasmids 137 + F1A, FIB 
106 - - 
81 + F1A, FIB 
9T E.coli J62-2 Plasmid 78 + FIB 
10T E.coli J62-2 Plasmid 106 + F1A, FIB 
25T E.coli J62-2 Plasmid 127 +  F1A 
 
 
The blaCTX-M-15 allele was observed on a single plasmid found in each strain. 
However, this gene was found on two plasmids in one strain with multiple plasmids 
Table 5.1 and Figure 5.6. It is important to note that the plasmid sizes in the three 
transconjugants did not match the sizes of the plasmids in the original strains. This 
was a repeatable result on a number of occasions and may reflect either plasmid 
rearrangement or, more likely, that some of the plasmids in the original isolates were 
masked during the extraction procedure. What is particularly important to note that a 
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single plasmid does not seem to be responsible for disseminating the cephalosporin 
resistance determinant. This is confirmed in the Figure 5.6 which shows that the 
blaCTX-M-15 gene is being carried on plasmids of different sizes. 
 
 
Figure 5.6: PCR amplification of CTX-M-15 β-lactamase genes (903 bp band) of 
plasmids for the isolates and transconjugants. Lane M: 1 Kb marker. Lane N: 
negative control (free DNA). The isolate numbers are shown at the top of each lane. 
Those that have the suffix T are transconjugants from these isolates. Those with a, b, 








250 bp  
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5.6. Genome Walking and Simplex PCR for genetic environment 
studies 
 
Insertion sequences such as ISEcp1 have been associated with blaCTX-M-15 (Karim et 
al, 2001), often these are located upstream of the blaCTX-M-15 genes. Furthermore, the 
expression of blaCTX-M-15 genes needs the presence of a promoter and these insertion 
sequences upstream of blaCTX-M genes may provide one, though their major role is in 
the mobility of the gene (Lartigue et al, 2006). Studies have shown that there is a 
variety of flanking regions surrounding these genes (Cantón and Coque, 2006; 
Carattoli, 2011;Woodford et al, 2011); however most comprise just small variations 
of a coomon genetic backbone (Lartigue et al, 2004; Eckert et al, 2006; Dhanji et al, 
2011b; Toleman and Walsh, 2011). These have undoubtedly enabled the spread of 
the gene as they have contributed to it selective advantage (Baquero, 2004; Cantón 
and Ruiz-Garbajosa, 2011; Canton, Gonzalez-Alba, and Galan, 2012). 
 
ISEcp1 is the most frequently detected insertion sequences upstream of blaCTX-M 
genes. Although further insertion sequences have been described upstream of the 
blaCTX-M genes, such as ISCR1, IS10 and IS26, Other insertion sequences elements 
have also been identified upstream but they were the result of integration events. For 
example, IS10 and IS1, IS26 and even ISCR1, have been shown to insert in and 
interrupt ISEcp1 (Eckert et al, 2006; Bae et al, 2008). Although it was first found 
joined to the blaCTX-M-15, it has been detected associated with all groups of β-




The spacer sequences between ISEcp1 and blaCTX-M genes are related to the MICs of 
cephalosporins (Ma et al, 2011). These genetic distances ranged from 48 to 127 bp in 
blaCTX-M-15 gene cluster (Canton, Gonzalez-Alba & Galan, 2012). When the 
homology among Genetic spacer sequences of blaCTX-M-1 genes cluster was 
examined, all except blaCTX-M-10 and blaCTX-M-53 maintained a common sequence 
region. Thus, these blaCTX-M genes of blaCTX-M-1 group might be originated from a 
single transposition event (Canton, Gonzalez-Alba, and Galan, 2012).  
 
The genetic environment of the blaCTX-M-15 gene in the six isolates was examined the 
flanking regions were sequenced. This was obtained by initial sequencing of the gene 
blaCTX-M-15 gene and then using this sequence to design new primers, sequencing the 
upstream region and downstream region as well. The primers used for gene walking 
detection were listed in Table 2.7 in the Materials and Methods section. These PCR 
amplifications are shown in Figures 5.7, 5.8, 5.9 and 5.10. 
 
Interestingly, these genetic arrangements show high similarity which indicates the 
circulation of a certain plasmid harbouring blaCTX-M-15 gene in the hospital wards. 
These findings were confirmed by the existence of the both IncF1A and IncF1B in 







Figure 5.7: PCR amplification of genetic environment positive isolates 9 and 10 
(2400 bp), and positive isolates 9T and transconjugant 10T (1600 bp). Lanes M: 1 
Kb marker. Lane N: negative control (free DNA). The isolate numbers are shown at 
the top of each lane. The respective isolates are E. coli 9, 10, 12, 23, and 25, E coli and 


















Figure 5.8: PCR amplification of genetic environment positive isolates 12 and 23 
(1700 pb). Lanes M: 1 Kb-pb markes. Lane N: negative control (free DNA). The 
isolate numbers are shown at the top of each lane. The respective isolates are E. coli 
9, 10, 12, 23, and 25, E coli and K. pneumoniae strain 60, Those that have the suffix T are 
















Figure 5.9: PCR amplification of genetic environment positive isolates 25 and 25T 
(2500 pb). Lanes M: 1 Kb marker. Lane N: negative control (free DNA). The isolate 
numbers are shown at the top of each lane. The respective isolates are E. coli 9, 10, 
12, 23, and 25, E coli and K. pneumoniae strain 60, Those that have the suffix T are 
transconjugants from these isolates. 
 
 

















Figure 5.10: PCR amplification of genetic environment (downstream) positive 
isolates 9, 10, 12, 23, 25, 60, 10T, and 25T (1300 pb). Lanes M: 1 Kb marker. Lane 
N: negative control (free DNA). The isolate numbers are shown at the top of each 
lane. The respective isolates are E. coli 9, 10, 12, 23, and 25, E coli and K. pneumoniae 
strain 60, Those that have the suffix T are transconjugants from these isolates. 
 
The variable region has been sequenced in each isolate and the data are shown in 
Figure 5.11 and the comparisons are shown diagrammatically in 5.12. It should be 
noted that orf477 was found downstream in every case; the purpose of this gene is 
unknown and further downstream studies were not undertaken.  
The orf477 was found in different lengths in each isolate; 129 bp in isolates 9 and 10, 
135 bp in isolates 12 and 25, and 127 bp in isolates 23 and 60 (Figure 5.12) 










Figure 5.11: Insertion sequences differences size of each isolate of the upstream 

















































Figure 5.12: Schematic representations of six environments surrounding blaCTX-M-15 
















































A summary of all isolates examined by gene walking primers, GenBank No., ISEcp1 
size, W region size, and promoters are listed in Table 5.2. 
 
Table 5.2: Upstream structure size for each isolates examined by gene walking 




accession No.  
ISEcp1  W region 
size (bp) 
orf477 




9 HQ157356.1 206 + + 48 TQ4325591 
10 HQ157356.1 206 + + 48 TQ4325591 
12 HQ157353.1 544 + + 48 TQ4325591 
23 HQ157353.1 495 + + 48 TQ4325591 
25 JN788267.1 171 + + 48 TQ4325591 
60 HQ157356.1 223 + + 48 TQ4325591 
 
 
The “W” region or spacer (48 bp) was also analysed in this study. The results 
showed the presence of two promoters in each “W” region of each isolates. These 





5.7. Integrons carriage by Escherichia coli isolates producing ESBLs 
enhancing resistance   
Integrons are elements which comprise the genetic determinants of a site specific 
recombination system able to identify and catch mobile gene cassettes. This element 
contains integrase gene (int) adjoining recombination site gene (attI) and a promoter. 
In addition, there is a part of integron called cassette which does not necessarily exist 
automonously, but when integrated, become part of the integron (Hall & Collins, 
1995). Usually, gene cassette requires a promoter for its expression. So, if the 
integrated cassette is the close to the promoter, the highest rate of expression will be 
given in the integron (Collis & Hall, 1995).  
 
Two main groups of integrons have been reported; chromosomal integrons and 
mobile integrons. Chromosomal integrons are present in most bacterial species 
chromosome (Cambray, Guerout & Mazel, 2010). Some are found in bacteria such as 
Vibrio spp. and Xanthomonas spp. As these bacteria carry more than 200 cassettes, 
they have been termed superintegrons. On the other hand, mobile integrons are not 
autotransferable elements but have to be placed within mobile genetic elements such 
as plasmids and transposons. Moreover, mobile integrons usually compose a limited 
number of gene cassettes (Naas et al, 2001).The gene cassettes revealed in these 
mobile integrons often encode antibiotics resistance determinants. Therefore, mobile 
integrons are sometimes termed resistance integrons (Stalder et al, 2012). Three 
classes of resistance integrons (1 – 3) have been described (Hall and Collins, 1995). 
The majority of resistance integrons belong to class1 which have been observed in 
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many Gram-negative bacteria including Escherichia coli (Schmitz et al, 1999) and 
Klebsiella pneumoniae (Girlich, et al, 2000).  
 
This study showed one isolate with integron class1 with its transconjugant (Figure 
5.13) using primers listed in 2.22 in the Material and Methods section and the 
amplicons were then sequenced. 
 
 
Figure 5.13: PCR amplification of integron class 1 positive isolates 25 and 25T (898 
bp). Lanes M: 1 Kb marker. Lane N: negative control (free DNA). The isolate and 
transconjugant numbers are shown at the top of each lane  
 








PCR product was sequenced giving GenBank No. KC493654.1. The later result 
confirms the presence of class 1 integron integrase (intI1). Figure 5.14 shows the 
aligment of sequences of the positive product with Integron class 1. 
 
 
Figure 5.14: IntI1 sequences in isolate 25 are aligning with IntI1. Areas in red are 




Five strains of Escherichia coli and one Klebsiella pneumoniae harboured the 
blaCTX-M-15 gene. Two of the Escherichia coli strains appeared clonal by PFGE but 
there was no distinct relationship between these and the other strains. The blaCTX-M-15 
gene was transferable to E. coli J62-2 from three of the strains tested.  
 
Different lengths of truncated ISEcp1 (between 171 bp and 544 bp), flanked by IS26 
were detected in all isolates of containing the blaCTX-M-15 gene. Sequencing analysis 
indicated that in all my isolates there was a typical promoter region (-10 TACAAT) 
and (-35 TTGAA) within the 3’ non-coding terminus of ISEcp1 which has a crucial 
role in the increasing expression of blaCTX-M-15 (Poirel, Gniadkowski, and Nordmann, 
2002; Karim et al, 2000; Dhanji et al, 2011).  
 
Various blaCTX-M-15 genetic environments have been found among Escherichia coli 
isolated from samples obtained from overseas UK travellers, however the majority 
carried an intact copy of ISEcp1 situated 48 bp upstream of blaCTX-M-15. This 
backbone has also been reported in isolates from Canada, Italy, France, Spain, and 
the UK (Canton and Coque, 2006; Lovally et al, 2006; Boyd et al, 2004).  
 
My findings correlate with other reports, from Turkey and Germany, that indicated 
that the blaCTX-M-15 genes were located in IncFIA and IncFIB replicons, (Gonullu et 
al, 2008; Mshana et al, 2009). However, the IncFII replicons were the most common 
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associated with blaCTX-M-15 genes in Canada, Spain, France, and the UK (Boyd et al, 
2004; Hopkins et al, 2006; Karisik et al, 2006; Lavollay et al, 2006; Novais et al, 
2007). My findings in plasmids size in this study indicated that the blaCTX-M-15 genes 
were transferred by large plasmid in most isolates (Figure 5.6) (Table 5.1). The 
transferred plasmids indicate that the blaCTX-M-15 genes migrate in large conjugative 
plasmids which are well adapted and constantly exchange by lateral gene transfer 
between our collected isolates in this study.  
 
All isolates producing CTX-M ESBLs investigated in this study were recovered from 
area in London where there is a large sub-continent population. This may explain the 
reason for the existence of blaCTX-M-15, though it should be noted that the proportion 
is relatively small. We cannot exclude the possibility that some patients entered 
hospital already carrying ESBL positive strains, which would explain the diversity. 
On the other hand, the patients could have caught the strains from the hospital 
settings, though in this case a greater degree of similarity would be expected. 
 
The connection between enzyme type and location reflects the prevalence patterns 
for certain CTX-M β-lactamase types (Celenza et al, 2006; Mohamed Al-Agamy, El-
Din Ashour, and Wiegand, 2006). Recent studies from Sweden and Canada have 
revealed international travel to be an important risk factor for colonization of gut and 
community-acquired infections with Escherichia coli producing CTX-M ESBLs, 
reflecting the area or the country visited. For example, the CTX-M-15 β-lactamase is 
linked to Europe and India, CTX-M-9 and CTX-M-14 β-lactamases are linked with 
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the Far East and the CTX-M-2 β-lactamases has been linked to South America 
(Pitout et al, 2009; Tham et al, 2010). 
 
The results in this study correlates with previous studies that the CTX-M-15 β-lactamase 
is the predominant member of the group (Novais et al, 2007; Nicolas-Chanoine et al, 
2008; Pitout, 2010; Peirano and Pitout, 2010; Woodford et al, 2006; Coelho et al, 
2010) and confirming that it is the most prevalent member of ESBLs in the UK is 
blaCTX-M-15 gene (Mushtaq et al, 2003; Woodford et al, 2004). Findings in this study 
suggest an overall similarity, though with crucial differences, of the genetic 
arrangement upstream of the blaCTX-M-15 gene among all the six isolates. This study 
suggesst that there possibly was a clone, exemplified by isolates 9 and 10 and the 
blaCTX-M-15 gene was located on different plasmids providing the opportunity to 
spread the gene among different strains. This suggests that within this population 
there was diversity both amongst the isolates and the plasmids carrying the blaCTX-M-
15 gene. 
 
The genetic context of all six isolates in this study was previously described to be the 
“international blaCTX-M-15 genetic environment” (Diestra et al., 2009). This genetic 
environment was not specific for Escherichia coli strains only as it was also found in 
the strain of Klebsiella pneumoniae. Common structures of the international genetic 
environment of blaCTX-M-15 gene are; the “W” region, a disrupted ISEcp1 sequence 
involved promoters which increase expression of the downstream blaCTX-M-15 gene, 




The spread of blaCTX-M-15 gene is probably associated to the presence of the insertion 
sequence, ISEcp1. A strong association between the blaCTX-M-15 gene and ISEcp1 has 
been described in literature (Poirel et al, 2003; Sonnevend et al, 2006; Naseer et al, 
2009; Ma et al, 2009). Furthermore, blaCTX-M-15 gene acquisition has often been 
reported to be mediated by ISEcp1 (Yu et al, 2011). Indeed insertion sequences have 
been shown to capture, mobilize, transpose and express of different blaCTX-M genes 
(Sonnevend et al, 2006, Sun et al, 2010, Zong et al, 2010). ISEcp1 was present 
sequences of all blaCTX-M genes in this study, but with variable degrees of truncation 
(Figure 5.8). Similar variations have been described in previous studies (Kiratisin et 
al, 2007, Novais et al, 2007; Dhanji et al, 2011) but not with strain found in such 
close proximity, which suggests that the plasmids from the strains from St George’s 
hospital are not so closely related. Interestingly, a similar study in strains from 
Scotland showed far less variation in the truncation of ISEcp1 (Dimude & Amyes, 
2012). Further indicator of mobilization is the presence of sequences of orf477 (Zong 
et al, 2010). This result was seen downstream of blaCTX-M-15 gene in all six isolates in 
this study. 
 
ISEcp1 is not limited to the capture and mobilization of blaCTX-M-15 genes; it also 
enhancing the expression of the downstream blaCTX-M-15 gene (Dutour et al, 2002; 
Eckert et al, 2006; Ma et al, 2011; Peirano and Pitout, 2010). A study by Ma et al (2011) 
revealed that the truncation of ISEcp1 adjacent to the blaCTX-M-15 gene affects the 
expression of the gene (Ma et al, 2011). This is because the –35 and –10 promoter 
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sequences reported by Poirel et al (2003) ‘’TTGACA’’ and ‘’TAAACT’’ were also 
detected in the upstream sequences of blaCTX-M-15 of all six isolates in this study. 
  
Further analysis, the closest promoter sequences detected in the upstream of blaCTX-
M-15 was detected to be residing in the “W” sequences. The promoter sequence 
reported by Dhanji (2011) “TTCAG” was detected in the “W” region of the six 
isolates in this study. The role of the conserved spacer “W” and explanation of its 
present upstream blaCTX-M-15 remains unclear.  
 
Further investigation of the region of “W” on our six isolates was revealed that it did 
not only harbour promoter required for the downstream blaCTX-M-15 genes expression, 
but also it had the sequence of Shine-Dalgamo ribosomal binding “AAGGAA” 
adjacent to the start codon the downstream blaCTX-M gene (Shine and Dalgarno, 
1974). The role of these sequences is associated with protein translation. They recruit 
ribosomes to mRNA for the induction of protein synthesis by aligning them with the 
start codon (ATG) of the downstream gene. The later sequences were detected in all 
of the “w” sequences upstream of all blaCTX-M-15 genes in this work.  
 
Class 1 integrons are located on plasmids and transposons, create the majority of the 
integrons detected in the clinical isolates and are related to the multidrug resistance 
observed in the hospital environment (Martinez-Freijo et al, 1998). The presence of 
gene cassettes as a component of Integron class 1 confers resistance to sulphonamide 
(cotrimoxazole). Class 1 integrons commonly include an additional resistance gene, 
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All our isolates harboured the international blaCTX-M-15 genetic environment. This 
arrangement shows truncated copy of ISEcp1 situated 48 bp upstream of blaCTX-M-15. 
Environments that included truncated ISEcp1 elements all included the (–35 
TTGAA) (–10 TACAAT) promoter within the 3′ non-coding segment involved in the 
transcriptional of blaCTX-M-15. A (–35 TTGACA) and (–10 TAAACT) promoter 
sequences were also detected in the upstream sequences of blaCTX-M-15 of all six 
isolates in this study. All these finding suggest that as long the increased number of 
promoters within upstream of blaCTX-M-15 gene, the high MICs showed in such 
isolates. Our study also suggests the impact of travellers on presence and spread of 
specific genetic arrangement of blaCTX-M-15 gene. In addition, this study shows a link 












Aim 1. In this study, the detection of ESBLs producing isolates was done by two 
methods; the double agar dilution method to determine the MICs for three 
cephalosporins (cefotaxime, ceftazidime, and ceftriaxone) and by the double disc 
diffusion method with cefotaxime, ceftazidime, and clavulanic acid. The spread of 
cefotaxime resistance in St George’s London hospital was concerning. For further 
detection and confirmation of the ESBLs producing isolates, PCR was used. The 
results revealed that the CTX-M-ESBL-producing were responsible for 
cephalosporin resistance in five isolates of E. coli and one isolate of K. pneumoniae. 
 
Aim 2. To fulfil the second aim of this work, the MICs were carried out using 
different classes of antibiotics. The determination of MIC was determined by the 
double agar dilution method explained by BSAC. Interestingly, co-resistance to 
fluoroquinolones and aminoglycosides was detected in all ESBLs producing isolates. 
In addition, this work found that all ESBLs producing isolates in both strains were 
detected to be susceptible to carbapenems. 
 
Aim 3. PFGE technique was used to determine the relatedness among the CTX-M-
producer isolates. This technique was used to study the clonality of these isolates. 
However, the results of PFGE indicated the genotypic similarity in only two of the 





Plasmid characterization can be detected by S1 nuclease digestion. This technique 
following PFGE method but using enzymes called S1 nuclease to convert 
supercoiled plasmids into linear molecules. This study indicated the presence of, at 
least, one plasmid for each isolates ranging from 78 kb to 152 kb. After extraction 
and amplification by PCR, plasmids showed replicon type of IncF1A and IncF1B in 
most of the isolates, suggesting the presence of certain plasmids moving from 
bacterium to bacterium within the hospital environment. In addition, blaCTX-M-15 
genes were detected on most plasmids found in these isolates.  
 
Aim 4. With further PCR amplification and sequencing, this project confirmed that 
blaCTX-M-15 is the most prevalent enzyme in St George’s London hospital and its gene 
product the causative enzyme of cephalosporin resistance. Moreover, the results of 
this study correlate with previous studies from the UK describing CTX-M-15 to be 
the commonest ESBL present in the UK.  
 
Aim 5. Mobile genetic structures were the main factors leading to increased spread 
and acquisition of resistance genes. This study focused on studying the genetic 
environments of blaCTX-M-15 and possible genetic elements associated with its spread. 
Gene walking PCR, plasmid sizing, and conjugation studies assessed this purpose. 
The results of gene walking PCR showed that ISEcp1was the commonest element of 
the upstream arrangement of all reported blaCTX-M-15. This confirms that ISEcp1 
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could be the main factor for the increased spread of blaCTX-M-15 and responsible for 
horizontal genetic transfer. 
 
This project shows the molecular diversity associated with the spread of blaCTX-M-15 
in a major teaching hospital in London. This diversity was observed by different 
lengths of ISEcp1 upstream of blaCTX-M-15 genes. In addition, diversity of this gene 
and its dissemination was shown by different phylogenetic group (A & B2) among 
the studied isolates. Moreover, the diversity was also represented by the carriage of 
this gene by both IncFIA and IncFIB plasmids in most of the isolates; it is 
uncommon that these together carry blaCTX-M-15 genes.  
 
On the other hand, the genetic arrangement of blaCTX-M-15 genes showed orf477 
downstream of blaCTX-M-15 in all CTX-M-15 producers. In addition, a typical 
promoter region (-10 TACAAT) and (-35 TTGAA) was found within the ISEcp1 of 
CTX-M-15 producers which has a crucial role in the increasing expression of 
blaCTX-M-15. Furthermore, the “W” region was 48 bp distant upstream between 
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Cefotaxime Ceftriaxone Ceftazidime Ertapenem Imipenem Meropenem Gentamicin Ciprofloxacin 
1 E. coli 0.06 0.03 0.12 0.5 0.03 0.03 1 0.5 
2 E. coli 0.06 0.03 0.12 0.5 0.03 0.06 1 0.5 
3 E. coli 0.25 0.06 0.03 0.25 0.008 0.06 32 16 
4 E. coli 0.06 0.06 0.03 0.5 0.008 0.12 0.5 8 
5 E. coli 0.06 0.06 0.12 0.06 0.015 0.12 8 0.5 
6 E. coli 0.06 0.12 0.25 0.06 0.015 0.008 8 1 
7 E. coli 0.06 0.12 0.25 0.25 0.015 0.008 1 1 
8 E. coli 0.06 0.06 0.25 0.5 0.008 0.008 0.5 1 
9 E. coli 64 32 8 0.5 0.015 0.015 8 8 
10 E. coli 32 32 8 0.5 0.12 0.015 8 8 
11 E. coli 0.06 0.03 0.06 0.5 0.25 0.015 64 8 
12 E. coli 64 128 16 0.5 0.008 0.06 8 16 






Cefotaxime Ceftriaxone Ceftazidime Ertapenem Imipenem Meropenem Gentamicin Ciprofloxacin 
14 E. coli 0.06 0.25 0.12 0.03 0.015 0.03 0.25 32 
15 E. coli 0.12 0.06 0.12 0.06 0.12 0.06 0.5 16 
16 E. coli 0.06 0.06 0.12 0.12 0.12 0.008 1 1 
17 E. coli 0.06 0.06 0.25 0.12 0.12 0.12 1 0.5 
18 E. coli 0.06 0.25 0.25 0.06 0.12 0.015 0.5 1 
19 E. coli 0.06 0.06 0.25 0.5 0.008 0.015 0.25 16 
20 E. coli 0.06 0.06 0.5 0.5 0.008 0.12 8 0.5 
21 E. coli 0.06 0.03 0.12 0.12 0.015 0.25 8 1 
22 E. coli 0.06 0.25 0.12 0.12 0.03 0.5 16 8 
23 E. coli 64 128 8 0.03 0.12 0.008 16 16 
24 E. coli 0.12 0.06 0.06 0.03 0.06 0.008 1 1 
25 E. coli 128 128 64 0.03 0.06 0.008 8 16 
26 E. coli 0.12 0.12 0.06 0.03 0.06 0.06 8 0.5 
27 E. coli 0.25 0.015 0.12 0.06 0.12 0.06 16 16 






Cefotaxime Ceftriaxone Ceftazidime Ertapenem Imipenem Meropenem Gentamicin Ciprofloxacin 
29 E. coli 0.06 0.06 0.12 0.03 0.008 0.03 8 8 
30 E. coli 0.5 0.06 0.06 0.5 0.12 0.015 1 8 
31 E. coli 0.06 0.25 0.5 0.5 0.25 0.015 1 32 
32 E. coli 0.06 0.03 0.25 0.5 0.008 0.008 1 16 
33 E. coli 0.06 0.03 0.25 0.5 0.015 0.06 0.5 16 
34 E. coli 0.06 0.06 0.12 0.06 0.015 0.015 0.25 16 
35 E. coli 0.06 0.12 0.12 0.5 0.12 0.5 1 1 
36 E. coli 0.06 0.25 0.12 0.25 0.25 0.008 0.25 0.5 
37 E. coli 0.06 0.12 0.12 0.12 0.008 0.06 0.5 0.5 
38 E. coli 0.12 0.06 0.12 0.06 0.015 0.03 0.5 64 
39 E. coli 0.25 0.06 0.12 0.03 0.015 0.03 0.5 32 
40 E. coli 0.06 0.03 0.06 0.03 0.03 0.008 1 8 
41 E. coli 0.06 0.03 0.06 0.06 0.12 0.015 32 8 
42 E. coli 0.06 0.06 0.12 0.06 0.008 0.015 16 8 






Cefotaxime Ceftriaxone Ceftazidime Ertapenem Imipenem Meropenem Gentamicin Ciprofloxacin 
44 E. coli 0.03 0.06 0.12 0.03 0.06 0.5 16 1 
45 E. coli 0.12 0.12 0.12 0.5 0.12 0.12 32 1 
46 E. coli 0.06 0.03 0.25 0.5 0.5 0.008 1 0.5 
47 E. coli 0.06 0.03 0.25 0.25 0.03 0.015 1 32 
48 E. coli 0.06 0.03 0.25 0.03 0.06 0.015 1 32 
49 E. coli 0.06 0.06 0.25 0.06 0.008 0.06 1 16 
50 E. coli 0.06 0.25 0.06 0.5 0.12 0.06 0.5 8 
51 K. pneumoniae 0.03 0.06 0.12 0.5 0.25 0.03 0.5 8 
52 K. pneumoniae 0.03 0.03 0.12 0.03 0.03 0.03 0.25 8 
53 K. pneumoniae 0.06 0.12 0.12 0.12 0.06 0.008 1 1 
54 K. pneumoniae 0.06 0.25 0.12 0.12 0.12 0.12 1 1 
55 K. pneumoniae 0.03 0.03 0.12 0.03 0.12 0.008 1 1 
56 K. pneumoniae 0.03 0.015 0.25 0.06 0.25 0.015 32 0.5 
57 K. pneumoniae 0.03 0.015 0.06 0.5 0.008 0.06 8 0.5 






Cefotaxime Ceftriaxone Ceftazidime Ertapenem Imipenem Meropenem Gentamicin Ciprofloxacin 
59 K. pneumoniae 0.06 0.06 0.5 0.5 0.03 0.008 0.5 8 
60 K. pneumoniae 128 128 128 0.06 0.06 0.03 8 16 
61 K. pneumoniae 0.06 0.06 0.12 0.06 0.12 0.03 1 8 
62 K. pneumoniae 0.03 0.06 0.12 0.03 0.008 0.06 0.5 8 
63 K. oxytoca 0.03 0.06 0.12 0.12 0.008 0.06 0.5 1 
64 K. oxytoca 0.03 0.06 0.12 0.03 0.06 0.008 0.25 1 
65 K. oxytoca 0.06 0.25 0.25 0.5 0.5 0.008 1 1 
66 K. oxytoca 0.06 0.06 0.25 0.06 0.008 0.12 1 0.5 
67 K. oxytoca 0.12 0.06 0.12 0.5 0.015 0.015 1 0.5 
68 E. cloacae 0.03 0.12 0.12 0.5 0.015 0.015 8 64 
69 E. cloacae 0.03 0.25 0.12 0.5 0.12 0.015 8 64 
70 E. cloacae 0.03 0.015 0.12 0.12 0.008 0.015 32 32 
71 E. cloacae 0.03 0.03 0.25 0.25 0.06 0.008 1 16 
72 E. cloacae 0.25 0.015 0.5 0.25 0.03 0.12 8 16 






Cefotaxime Ceftriaxone Ceftazidime Ertapenem Imipenem Meropenem Gentamicin Ciprofloxacin 
74 E. cloacae 0.25 0.06 0.5 0.25 0.06 0.06 16 32 
75 E. cloacae 0.06 0.03 0.12 0.25 0.06 0.008 16 32 
76 E.spp 0.25 0.03 0.12 0.5 0.06 0.008 16 1 
77 P. mirabilis 0.12 0.06 0.12 0.5 0.03 0.008 1 1 
78 P. mirabilis 0.03 0.06 0.12 0.06 0.008 0.06 1 0.5 
79 P. mirabilis 0.03 0.06 0.12 0.06 0.12 0.008 0.5 0.5 
80 P. mirabilis 0.03 0.03 0.25 0.06 0.015 0.008 0.5 0.5 
81 P. mirabilis 0.03 0.015 0.25 0.03 0.008 0.008 0.5 1 
82 P. mirabilis 0.03 0.12 0.25 0.03 0.06 0.06 1 1 
83 P. mirabilis 0.03 0.12 0.25 0.06 0.03 0.015 1 8 
84 P. mirabilis 0.03 0.12 0.12 0.5 0.03 0.015 1 8 
85 P. mirabilis 0.06 0.06 0.12 0.12 0.06 0.008 0.5 16 
86 P. mirabilis 0.06 0.06 0.5 0.12 0.008 0.03 0.25 32 
87 P. mirabilis 0.12 0.06 0.5 0.12 0.008 0.06 0.25 32 






Cefotaxime Ceftriaxone Ceftazidime Ertapenem Imipenem Meropenem Gentamicin Ciprofloxacin 
89 P. vulgaris 0.06 0.03 0.12 0.5 0.015 0.06 1 1 
90 LFC 0.06 0.03 0.12 0.5 0.12 0.03 0.5 1 
91 LFC 0.03 0.03 0.12 0.5 0.5 0.008 8 1 
92 LFC 0.06 0.12 0.06 0.5 0.03 0.015 8 0.5 
93 LFC 0.06 0.12 0.06 0.06 0.06 0.12 16 0.5 
94 LFC 0.06 0.12 0.06 0.03 0.015 0.5 8 0.5 
95 LFC 0.06 0.03 0.25 0.06 0.015 0.015 4 8 
96 Pantoea spp 0.06 0.06 0.12 0.12 0.008 0.06 1 8 
97 Pantoea spp 0.03 0.06 0.12 0.5 0.06 0.06 1 16 
98 Morganella 
morganii 
0.03 0.06 0.12 0.5 0.015 0.06 1 8 
99 Hafnia alvei 0.06 0.06 0.12 0.06 0.03 0.06 1 1 
100 Serratia 
marcescens 
0.03 0.06 0.12 0.5 0.03 0.03 1 0.5 
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